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5-FLUOROURACIL TOXICITY - AN IMPROVED DETECTION 
METHOD FOR THE INTRON 14 G TO A MUTATION 
ASSOCIATED WITH DIHYDROPYRIMIDINE 
DEHYDROGENASE DEFICIENCY
Susan D. Richman*, Julian W. Adlard. Academic Department of 
Pathology, Algernon Firth Building, University of Leeds, LS2 9JT. 
  Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme in 
the catabolism of 5-fluorouracil (5FU). DPD deficiency, seen in up to 3% of
the population, leads to severe 5FU toxicity and is most often due to a G to A
point mutation within the splice-site of intron 14. A published method of 
identifying this mutation has used PCR followed by digestion with the MaeII
restriction enzyme (1). However, this method lacks an internal control for the
digestion process. Incomplete digestion of wild type DNA can produce
similar results to DNA heterozygous for the mutation. Sequencing of the
PCR product may be necessary to confirm the mutation. Also, the MaeII
restriction endonuclease is expensive for use in large population or trial-
based studies. 
  We have developed a novel detection method, involving PCR of a 231
base pair product spanning the mutation site, followed by a restriction
digestion with Msl1. The method was validated on DNA from known
heterozygotes for the mutation (supplied by Dr. Howard McLeod, St. Louis,
USA) and wild-type controls. This technique avoids false positive results as
there is a splice site present in both the wild-type and mutant DNA which
acts as an internal control for complete digestion. A second spice site occurs
only when the G-A mutation is present, hence allowing detection of the
mutant allele. Heterozygotes and homozygotes for the mutation can be
distinguished. The small size of the PCR product makes this method suitable
for  analysis of DNA from a variety of sources including formalin-fixed 
paraffin-embedded specimens. The Msl1 restriction endonuclease is 
approximately 1/20th of the cost per unit compared with MaeII. 
  Our technique represents a more cost-effective method of screening
for the intron 14 DPD mutation associated with 5FU toxicity. 
Reference: 1) Wei, X et al. 1996. J Clin Invest. 98:610. 
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PHASE 1 STUDY OF MITOMYCIN-C (MMC) & CONTINUOUS
INFUSION (CI) 5-FU CHEMORADIATION IN LOCALLY
ADVANCED RECTAL CANCER (LARC). 
AH Sadozye
1, LM Samuel
2, L McMahon
1 and *AC McDonald
1 for the 
Colorectal Clinical Oncology Group. 
1  Beatson Oncology Centre, 
Glasgow G11 6NT  UK and 
2 Aberdeen Royal Hospitals.  
 
   Introduction  and  aims: CI 5-FU based chemoradiation (CRT) 
facilitates tumour downsizing in patients (pts) with LARC. Although 5-
FU is often delivered at 225mg/m
2/day, 7 days / week, optimal 
dose/scheduling remains unclear. The addition of MMC to CI 5-FU 
improves response rates in metastatic disease and MMC is a key 
component in anal cancer CRT. This phase 1 trial aims to determine the 
maximum tolerated dose of CI 5-FU / MMC combination CRT in pts 
with LARC.   M e t h o d s :  Pts were accrued sequentially to one of 4 
cohorts (3 pts / cohort) and received escalating doses of MMC (IV bolus 
day 1) and CI 5-FU (7days/week via PICC line). Cohort 1 MMC 
8mg/m
2 & 5-FU 200mg/m
2/day; Cohort 2 MMC 8mg/m
2 & 5-FU 
225mg/m
2/day; Cohort 3 MMC 10mg/m
2 & 5-FU 225mg/m
2/day; 
Cohort 4 MMC 10mg/m
2 & 5-FU 250mg/m
2/day. Pelvic radiotherapy 
(RT, 45Gy / 25#) was delivered to a CT-planned volume.   Results: Of 
13 pts (med age = 55yrs, 8 males) accrued, 12 have completed 
treatment. Two pts within cohort 4 had dose limiting toxicity (gd 3 PR 
bleeding=1pt, gd 3 diarrhoea=1pt). Significant (>gd 1) haematological 
toxicity was not seen. Eight pts have undergone resection (ypT1-2 
ypN0=2pts, ypT3-4 or ypN+=4pts, pCR=1pt, histology awaited 1pt). All 
8 pts had tumour-free circumferential resection margins. Four pts were 
not resected due to the development of interval metastatic disease. 
   Conclusion:  As part of CRT for LARC, MMC 10mg/m
2 is 
deliverable with standard CI 5-FU doses, with acceptable toxicity. 
Accrual continues at MMC 10mg/m
2 + 5-FU 250mg/m
2/day.  
 
Level  n   MMC dose  5-FU dose 
1 3  8mg/m2 200mg/m2/day 
2 3  8mg/m2  225mg/m2/day 
3 3  10mg/m2   225mg/m2/day 
4 3  10mg/m2   250mg/m2/day 
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POTENTIATION OF RALTITREXED (RTX) IN VITRO BY
THYMIDINE PHOSPHORYLASE (TP) AND TP 
DISTRIBUTION IN VIVO 
Claire L. Graham*, H. D. Thomas, R. Melton#, G.A.Taylor, D.R 
Newell, A.V. Boddy. Northern Institute for Cancer Research, 
University of Newcastle, NE2 4HH. #Enact Pharma Plc, Salisbury. 
   RTX is a classical thymidylate synthase (TS) inhibitor used to 
treat colorectal cancer. Inhibition of TS by RTX leads to a dose 
dependent depletion of dTTP, which is required for DNA synthesis 
and repair. Tumours may circumvent TS inhibition by salvage of 
endogenous thymidine (TdR). TP can convert endogenous TdR to 
thymine and deoxyribose-1-phosphate, thus reducing available 
TdR for salvage. 
   In vitro 3µM TdR is sufficient to reverse RTX growth inhibition 
in colorectal carcinoma cell lines. In the presence of TdR, RTX 
growth inhibition can be potentiated by the addition of 0.005 – 
0.025 units/ml of TP. 
   Mice bearing LoVo and HT29 xenografts were given 1Unit of 
TP i.v. TP and TdR were measured in the tumour (T) and plasma 
(P) 24, 48 and 72h after administration of TP. TP was measured as 
thymine formation nmoles/min/µg protein. TdR was measured as 
µM in plasma and nmoles/mg protein. Plasma TP was 
undetectable at each of the time points. 
LoVo HT29 Hours 
post TP   0  24 48 72 0  24 48 72
TdR    0.06 0.17 0.09 0.12 0.20 0.52 0.33 0.21 T 
TP  0.98 0.64 0.42 0.51 0.19 0.14 0.16 0.10
P TdR 0.38 0.49 0.56 0.42 0.75 0.70 0.63 0.51
   As the native protein TP does not accumulate in the tumour, in 
contrast to the results seen when TP is conjugated to an anti-CEA 
antibody. 
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ROLE OF CYCLOOXYGENASE-2 IN LIVER METASTASES
ARISING FROM COLORECTAL CARCINOMA
Milind Rao*, Wenxuan Yang, Alexander M. Seifalian, Marc C.
Winslet. University Department of Surgery, Royal Free and
University College Medical School, University College London
and The Royal Free Hospital, London, UK
Aim: Cyclooxygenase-2 (COX-2) is involved in the development 
of colorectal carcinoma but its role in liver metastases is not 
established. We aimed to study the COX-2 expression and the 
effect of Rofecoxib, a selective COX-2 inhibitor in a rat model of 
liver metastases. Methods: 6 BD1X rats (Control) were inoculated 
with DHD/K12 colorectal cancer cell line (5 x 10
6) through intra-
portal injection and metastases were examined three weeks after 
inoculation. In another group, 6 BD1X rats (Rofecoxib) were fed 
with Rofecoxib (10mg/kg body weight /day) for 3 weeks following 
inoculation. COX-2 expression in liver tissue and metastatic 
tumour was detected using conventional and fluorescent 
immunohistochemistry observed under confocal microscopy. 
Results: Liver metastases developed in all animals three weeks
after inoculation. No metastases were seen anywhere outside the 
liver. There were no differences in the number of metastatic 
nodules between control and Rofecoxib groups (230 vs. 249). 
COX-2 was expressed in both the metastatic tumour cells and the 
hepatocytes (around the central vein and the vicinity of the 
tumour). Fluorescent staining further supported these findings. 
Notably, the intensity of staining of tumour tissue was higher than 
that in the surrounding hepatocytes. Also, COX-2 positive staining 
was seen mainly in the cytoplasm of metastatic tumour cells while 
it only presented in the nuclei of the hepatocytes. Conclusion:
COX-2 is expressed in liver metastases and the surrounding liver 
tissue. Rofecoxib did not reduce number of liver metastases.
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A RANDOMISED TRIAL OF IRINOTECAN UNTIL DISEASE
PROGRESSION (PD) VERSUS 8 CYCLES ONLY IN
FLUOROPYRIMIDINE-RESISTANT ADVANCED COLORECTAL
CANCER (CRC)
Kumar R. Lal*, Paul J Ross, Andrew R Norman, Alison Massey, Mark
Hill, Gary Middleton, Claire Topham,David Cunningham.
Royal Marsden Hospital, Downs Road, Sutton, SM2 5PT. 
Irinotecan continued until PD is standard of care for patients with 
fluoropyrimidine-resistant CRC.  We evaluated the optimal duration of 
irinotecan therapy in a randomised trial comparing stopping treatment
after 8 cycles to continuing until PD.  333 patients (pts) with locally
advanced or metastatic CRC that had PD on or within 24 weeks of 
completion of fluoropyrimidine therapy received irinotecan 350mg/m
2 3-
weekly.  After 8 cycles 230 pts had PD, 30 stopped due to toxicity, 2 
refused randomisation but continued irinotecan and 2 were withdrawn.
55 pts with stable or responding disease were randomised, 25 pts,
including 6 responders, to continue irinotecan and 30 pts, including 8
responders, to discontinue irinotecan.  The mean age of randomised pts
was 62.4 years (range 42-78) and demographics were balanced between
the 2 cohorts.  A total of 277 additional cycles were delivered to the 
continue irinotecan group, with a median of 12 cycles in total (range 9-
20).  There were no additional responses after randomisation.  Grade 3/4 
diarrhoea occurred in 8%; there was no grade 3/4 febrile neutropaenia.
16 patients randomised to stop irinotecan had further chemotherapy at 
PD, 8 with irinotecan. PFS at 6 months was 36.4% (95% CU 17.4-55.4%) 
in the continue irinotecan arm and 25% (95% CI 11.1-41.8%) in the stop
irinotecan arm (p=0.999).  Similarly there was no difference in 1-year
survival being 46.3% (95% CI 25.1-65.1%) in the continue irinotecan
arm and 54.8% (95% CI 34.2-71.4%) in the stop irinotecan arm (p=0.11).
Global quality of life scores 12 weeks after randomisation were not 
significantly different in the two groups (p=0.446).
Following 8 cycles of irinotecan the majority of patients have stopped 
treatment either due to PD or unacceptable toxicity.  However, for the 
16.5% of patients still benefiting from irinotecan there appears little 
advantage continuing beyond 8 cycles. 
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ESTIMATION OF PLASMA THYMIDINE IN HEALTHY
VOLUNTEERS VS. CANCER PATIENTS BY HIGH
PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)
Tim Benepal*, Fraser Mitchell, Isobel Gibbens, Martin Gore and
Ann Jackman. The Institute of Cancer Research, Sutton, Surrey.  
Two pathways exist for the formation of thymidylate; a) the de 
novo pathway with thymidylate synthase (TS) being a key step, 
and, b) the salvage pathway in which thymidine (dThd) is the 
substrate. The latter has the potential to modulate the 
efficacy/toxicity of TS inhibitors such as 5-fluorouracil, 
methotrexate and the more specific inhibitors, raltitrexed and 
ZD9331. Human dThd levels have been reported to range from 0.1 
to 7.4 µM (Holden et al, EJC, 1980) using radioimmunoassay, and 
to be higher in patients with haematological malignancies. Later, 
an HPLC technique quantified human and mouse levels of dThd to 
be <0.1µM and ~1µM respectively (Jackman et al, Biochem. 
Pharmacol, 1984). We have developed now a highly sensitive 
HPLC technique to accurately measure dThd. Plasma vs. serum 
dThd levels in 10 volunteers was compared with serum levels in 7 
patients with ovarian cancer. In addition, we evaluated the 
possibility of thymidine phosphorylase (TP) released from 
platelets artifactually lowering sample dThd levels, by addition of 
a TP inhibitor to paired samples from 7 volunteers. Mean plasma 
vs. serum values in the volunteers was 14nM (4.5-25) vs. 12nM 
(4.5-23, p=0.57). Patient serum levels were lower than volunteers 
with a mean of 5.1nM (4-8, p=0.007). Addition of the TP inhibitor 
made no significant difference to results (-TP = 22nM range 5-48; 
+TP = 19nM, range 5-47, p=0.47). We conclude that the normal 
range of plasma/serum dThd in healthy volunteers is 5 to 50 nM. 
Patients with ovarian cancer have lower serum dThd levels. Future 
studies should evaluate the impact of pre-treatment dThd levels on 
the efficacy/toxicity of TS inhibitors in relevant tumour types.   
Supported by CRUK. 
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CAPECITABINEAND MITOMYCIN C  (MMC) IS AN ACTIVE
REGIMEN FOR PATIENTS WITH METASTATIC COLORECTAL
CARCINOMA (MCRC) RESISTANT TO 5FU AND IRINOTECAN
S Rao∗, D Cunningham, P.J Ross, T Price, C Ward, A.R Norman,
M.E Hill
Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT
Introduction: 5FU and MMC has demonstrated superior efficacy 
compared to infused 5FU alone in MCRC. MMC up regulates the 
expression of thymidine phosphorylase and thus capecitabine in 
combination with MMC may produce greater antitumour activity. 
Objectives: To evaluate the safety and efficacy of capecitabine/MMC in 
MCRC resistant to 5FU and irinotecan.
Methods: An optimal 2-stage design was employed. Patients were 
required to have WHO performance status (PS)0-2, to be able to take oral 
medications, and to have adequate haematological, renal and hepatic 
function. All patients demonstrated progressive disease on chemotherapy 
or within 6 months of cessation. Capecitabine (1250mg/m2 orally) was 
administered twice daily for 14 days followed by 7 days rest, every 
3weeks, and MMC (7mg/m2 IV bolus) was given every 6 weeks. CT 
response assessment according to RECIST criteria took place at 12 and 24 
weeks.
Results: 31 patients have been accrued.17(55%) were male, median age 
was 64 (range 40-77) years, and 23 (74%) had PS0-1. 6 (19%) received 
5FU based adjuvant therapy and 2 (6%) had prior radiotherapy. Sites of 
metastatic disease were liver 74%, lung 16%, peritoneum 16%, and nodal 
12%. Of the 23 patients evaluable for response thus far, the ORR was 
22% (95% CI: 6.8 -40.7) and13 (57%) had stable disease. There were no 
grade 4 toxicities; grade 3 toxicitiesinclude hand-foot syndrome 23%, 
diarrhoea 3.9%,vomiting 11.5% and neutropenia 3.7% Symptomatic 
improvement was as follows: pain 85%, dypsnoea 100% andbowel 86%.
Conclusion: Capecitabine and MMC is an active, well -toleratedregimen 
and is a valuable treatment option in MCRC refractory to 5FU and 
irinotecan. 
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ACUTE AND LATE TOXICITY FOLLOWING CONCURRENT
WEEKLY CISPLATIN AND RADIOTHERAPY FOR
CERVICAL CARCINOMA 
Margaret King 
1*, Chris McConkey 
2, Andrew Hartley
1, Indy 
Fernando
1 
1Cancer Centre, Queen Elizabeth Hospital, Birmingham B15 2TH 
2Cancer Research UK Clinical Trials Unit, University of 
Birmingham 
  Introduction  A recent meta-analysis has shown a survival 
advantage for the addition of concurrent chemotherapy to 
radiotherapy in the treatment of cervical carcinoma. Controversy 
persists as to the potential magnitude of benefit and toxicity. A 
single centre experience is presented. 
  Methods  All patients treated with concurrent chemo-
radiotherapy from the 1
st January 1999 to the 1
st May 2002 were 
identified. Acute and late complications were scored using the NCI 
Common Toxicity Criteria and RTOG/EORTC system 
respectively. Univariate and multivariate analysis were performed 
to examine the relationship between demographics, stage, overall 
treatment time, radiotherapy dose, selectron insertion , number of 
chemotherapy cycles and occurrence of acute and late toxicity. 
  Results  79 patients received concurrent weekly cisplatin 
(40mg/m
2) with radiotherapy. Survival rate at 12 months was 91% 
(95% confidence interval 84-98%). At a median follow up of 18 
months: 27 (34.2%) patients experienced 45 episodes of acute 
grade 3/4 complications and 9 patients (11.7%) experienced 16 late 
grade 3/4 complications. There was a significant correlation 
between grade3/4 acute toxicity and subsequent late grade 3/4 
toxicity (p =0.002).  
  Conclusions  Weekly cisplatin 40mg/m
2  concurrent with 
radiotherapy is well tolerated. However, severe acute toxicity 
carries a higher risk of subsequent late effects raising the possibility 
of consequential damage. 
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MALIGNANT MIXED MESODERMAL TUMOURS OF THE 
OVARY: A RETROSPECTIVE REVIEW 
Ewan Brown*, Moira Stewart, Tzyvia Rye, Awatif Al-Nafussi,  
Alistair R Williams, John Smyth, Hani Gabra
Cancer Research UK, University of Edinburgh Cancer Research
Centre, Crewe Road South, Edinburgh, UK. 
   Background:  Malignant Mixed Mesodermal Tumours
(MMMTs) are relatively rare epithelial tumours that consist of
both a carcinomatous and sarcomatous component. 
   Methods:  Between 1984-2002, 69 patients with ovarian
MMMT were referred to the Edinburgh Cancer Centre and
variables including age, performance status, CA125 level,
tumour stage, histological sub-type and type of treatment
received were prospectively recorded. Outcome measures
analysed were response to chemotherapy and overall survival. 
   Results: Patients had a median age of 67 (range 48-84). The
majority of patients had advanced stage of disease at
presentation (78% stage III/IV). Response rate (radiological and
CA125 response) for first-line chemotherapy was 45% (10/22
patients). Median survival of the entire series was 8.9 months
with a 1, 2 and 5 year survival rate of 44%, 24%, and 13%
respectively. Stage III patients who were optimally debulked
had a median survival of 12.1 months compared with 3.1
months for those who were sub-optimally or non-debulked.
Responders to chemotherapy had a median survival of 19.4
months compared to 5.5 months for non-reponders (p=0.0115). 
Conclusion: Ovarian MMMT is a distinct entity with poor
prognosis. Achieving optimal debulking at initial surgery is an
important factor in determining outcome and patients who
respond to chemotherapy have a significant survival benefit. This
analysis supports a role for chemotherapy and a need for
randomised trials in ovarian MMMT. 
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VAN DER BURG SCHEDULE (VDBS) IN RELAPSED
EPITHELIAL OVARIAN CANCER (REOC):CAMBRIDGE
ONCOLOGY CENTRE EXPERIENCE. Jennie Pratt, Bristi Basu,
Cheryl Palmer, Mahesh Iddawela, Jean Abraham, Swethajit
Biswas, James Brenton, Helena Earl*. Dept of Oncology,
Addenbrookes Hospital, Cambridge CB2 2QQ 
  Introduction: VDBS in REOC has been reported as tolerable 
with high response rates (RR) and acceptable toxicity. Aims: 
Evaluate RR and tolerability of VDBS in patients (pts) with REOC 
in Cambridge. Methods: 19 pts with REOC were treated with 
VDBS. Cisplatin dose tailored to prior cisplatin exposure: prior 
cisplatin (PC) 60mg/m
2, wk 1-3: no prior cisplatin (NPC) 60mg/m
2, 
wk 1-3, and 70mg/m
2, wk 5-7. Oral etoposide dose 50mg/d wk 1-2 
and 5-6. Dose intensity (DI) (dose delivered/dose planned) 
calculated. Response assessed by CT scan and Ca125. Toxicity 
assessed by CTC. Responding pts proceeded to maintenance oral 
etoposide (ME) (50mg/m
2/d 3wks x 6-9 cycles).  Results: Median 
no. prior regimens was 2 (range 1-5), median treatment-free-
interval (TFI) prior to VDBS was 5m (range 0.25-17m). 95% had 
prior taxanes;100% carboplatin;21% cisplatin. DI was 86% and 
83% in PC and NPC groups respectively. A median of 3 
cycles(range0-8) of ME was given. G3/4 toxicity: 
leucopenia(47%), fatigue(58%), anorexia(32%), infection(16%), 
diarrhoea(16%), N&V(58%). 3 deaths on induction treatment: 
neutropenic sepsis(1), bowel obstruction(1) and PE(1). Treatment 
stopped, delayed or dose-reduced due to toxicity in 84%. Following 
induction therapy radiological RR (CR/PR) was 64%, SD 27%, and 
Ca125 RR in those evaluable was 100%. Median progression-free-
survival (PFS) from start of induction therapy was 6m on Ca125 
and 7.75m on CT scan. Conclusions: VDBS in standard practice 
produced good RR and median PFS, but a high rate of toxicities, 
which should be taken into account given the palliative aim of 
treatment for pts with REOC. 
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A PHASE II TRIAL OF ETANERCEPT, A TUMOUR
NECROSIS FACTOR- α INHIBITOR IN RECURRENT
OVARIAN CANCER 
Sethupathi Ramalingam*, Susan Hoare,  Srinivasan
Madhusudan, Jeremy Braybrooke, Kulwinder Kaur, Sue
Willner, Adrian L.Harris, Francis Balkwill, Trivadi S.Ganesan.
CR UK Medical Oncology Unit, Churchill Hospital, Oxford 
OX3 7LJ, UK 
TNF-α is strongly expressed in ovarian cancer. We have 
conducted a phase II trial of etanercept, a TNF-α inhibitor in 
patients (pts) with recurrent ovarian cancer. Initially, 17 pts 
(cohort I) received etanercept (25mg SC twice weekly) and 
subsequently 13 pts (cohort II) were treated at 25mg SC thrice 
weekly. All pts were planned to receive a minimum of 3 
months of treatment up to maximum of 12 months. Disease 
response was evaluated at 3 monthly intervals. Surrogate end 
points for biological effects of etanercept included 
measurement of levels of TNF-α, TNF-R1, sE-Selectin, MCP-
1, MMP-3 in plasma and whole blood cytokine release 
inhibition assay for IL-6 and MCP-1. The time points were pre-
treatment, 24hours, 7 days, 28 days and 4 weekly there after. 
18/30 pts have completed ≥ 3 months of treatment. There was 
no significant toxicity. 4/25 evaluable pts achieved stable 
disease at 3 months, which was maintained in 3 at 6 months. In 
cohort I, 9/13 pts had a significant reduction in IL-6 levels on 
day 1 which was maintained until 12 weeks (6/8). MCP-1 
levels significantly declined in 9/13 pts on day 1 and by 3 
months was inhibited by 50% (6/6). All other surrogate 
markers did not change with treatment. Definite biological 
effect was seen with 3 months of etanercept therapy. The trial 
is ongoing in cohort II pts receiving etanercept 25 mg thrice 
weekly. 
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FEULGEN-LIGHT GREEN STAINING FOR CERVICAL
SMEARS
J. Stephen *, Anitha B, J Sreeja, TKG Nair, VG Chellam.
* 'Beth-Shalom', TC 11/1326, Bains Compound, Nanthencode,  
Trivandrum 695003, INDIA.  e-mail: jstephen@vsnl.com
Aim: To develop an alternative method for cervical smear staining. 
Procedure: Cervical smears were made from 60 clinically
suspected cases of carcinoma for the outpatients of Government 
SAT Hospital, Trivandrum, India together with those from ten 
healthy women as controls. Duplicate slides were made from each 
individual, one set stained by Papanicolaou method, the other by
Feulgen light green method and examined under Leitz research 
microscope. 
Major findings: Feulgen-light green staining was found to be 
superior to Papanicolaou staining in revealing finer details of 
nuclei and chromosomes which stained bright magenta in a light 
green cytoplasmic background. The light green Feulgen stain 
showed better affinity to cancer and precancer cells than to normal 
cervical cells. The study also revealed that the presence of
micronuclei and more than one Barr body per nucleus is associated 
with cervical carcinoma progression. 
Significance: Feulgen stained preparations can be used in 
automated DNA determination per nucleus by
microspectrophotometry and can be employed in rapid screening 
for carcinoma of the cervix.  
Conclusion: Feulgen-light green staining is a superior and sensitive 
method to detect carcinoma of the cervix. 
References: 
Feulgen, R; Rossenbeck, H 1924. Z.Physiol.Chem. 135:203 
Papanicolaou GN. 1942. Science 95:438 
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CARBOPLATIN (C)  FOLLOWED BY SEQUENTIAL WEEKLY
PACLITAXEL (T) AND GEMCITABINE (G) AS FIRST-LINE
TREATMENT FOR OVARIAN CANCER. M. Harries*, C. Moss,
T. Perren, M. Gore, G. Hall, M. Everard, R. A’Hern, C. Cole, I.
Gibbens, A. Jenkins and S. Kaye. Royal Marsden Hospital. 
 
Objectives: We evaluated the feasibility of delivering C followed 
by sequential weekly T and G in patients with advanced, previously 
untreated ovarian cancer. 
Methods: Women with FIGO stage Ic-IV ovarian cancer were 
treated with 4 cycles of C AUC 7 q21  followed by 4 cycles of T 70 
mg/m
2 (d1, 8, 15) and G 1000 mg/m
2 (d1, 8) q21. 
Results: 53 patients enrolled, with a median age of 59 years (range, 
29-77). 37 (70%) patients had FIGO stage III/IV and 22 (42%) had 
residual disease >2 cm. 29 (55%) patients completed all planned 
cycles of treatment. 24 patients stopped early, including 4 with 
progressive disease and 7 with pulmonary toxicity. Of 370 total 
cycles of chemotherapy delivered, 27 cycles required a dose 
reduction and 68 cycles were delayed, primarily due to 
myelosuppression, during the weekly phase. Of the 26 patients with 
radiologically evaluable disease, 23 (88%) had partial or complete 
responses. Of 36 patients with an elevated CA-125 at baseline, 30 
(83%) had a decrease >75%. CTC grade 3/4 hematological toxicity, 
predominantly neutropenia, was seen in 58% of cycles. The most 
significant non-hematological toxicity was pulmonary, which was 
reported in 7 (13%) patients with breathlessness, decreased transfer 
factor +/- radiological interstitial lung changes during the weekly 
phase of treatment. This toxicity was reversible and required 
steroids in only 2 patients. No significant neurotoxicity was seen.  
Conclusions: This regimen is generally well tolerated and 
associated with an acceptable response rate. However, the level of 
pulmonary toxicity, which may be a feature of the weekly taxane-G 
regimen, was of some concern. Thus, alternative schedules, 
including three-weekly taxanes, are currently being evaluated. 
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A PHASE II TRIAL OF CAPECITABINE AND MITOMYCIN 
C (MMC) IN 1st LINE TREATMENT OF METASTATIC 
COLORECTAL CANCER (MCRC). 
S Rao∗, D Cunningham, P.J Ross, T Price, D Watkins, A.R Norman, 
P Shellito, M.E Hill  
Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT 
Background: The combination of Mitomycin C (MMC) and infused
5FU has been shown to have greater efficacy than infused 5FU alone
in the treatment of MCRC. MMC is known to upregulation
intratumoural thymidine phosphorylase (TP) expression. The
upregulation of intratumoural TP by MMC may be exploited by the
use of MMC in combination with the oral fluoropyrimidine
capecitabine. This phase II study evaluates the efficacy and
tolerability of MMC and capecitabine combination as initial therapy
in MCRC. 
Methods: Eligibility; no prior chemotherapy for advanced disease or
adjuvant therapy in previous 6 months, measurable disease, ECOG
performance status (PS) ≤2. Patients (pts) received MMC 7mg/m
2 IV
bolus every 6 weeks and oral capecitabine 2500mg/m
2/day given for
14 days followed by 7 days rest (every 3 weeks), pts completed a
total of 24 weeks of therapy. CT response assessment was performed
every 12 weeks according to RECIST criteria. 
Results: Toxicity data is available on 46 pts and response data on 44
pts who have completed >12 weeks of treatment. Median age 70
(range 30-82) years, 67% of pts had ≥2 sites of disease. Objective
response rate is 45.4% (95% CI; 30.4%-61.1%) in evaluable pts,
stable disease was seen in a further 26.6%. Median failure free
survival is 7.6 months. No grade 4 toxicity occurred, grade 3
toxicities include; hand-foot syndrome 24%, diarrhoea 11%,
neutropenia 4%, nausea and vomiting 2.2%. 
Conclusion: Capecitabine /MMC appears to show promising activity
in MCRC with an acceptable toxicity profile and a convenient
administration schedule.  
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QUALITY OF LIFE AFTER 5YEARS TAMOXIFEN FOR
WOMEN WITH EARLY BREAST CANCER. P Hall, J 
Walkington, S Douglas, L Renshaw,  D A Cameron Edinburgh 
Breast Unit, Western General Hospital, EDINBURGH  EH4  2XU 
With no clear evidence suggesting a breast cancer benefit for 
continuing tamoxifen beyond 5 years, we were interested in the 
effect of stopping tamoxifen on patients’ quality of life (QoL). 
With local ethics approval, patients identified as being disease free 
and having completed 5 years’ tamoxifen patients were recruited. 
After giving written consent, patients completed the EORTC QLQ
C30, together with supplementary questions relating to other 
possible tamoxifen side effects.  Three months after stopping their 
tamoxifen, they were sent the same questionnaires to be returned 
by post. 46 have completed both questionnaires, with an average 
age of 61. Baseline QoL was similar to normal populations. Three 
months later there was no overall change in QoL for these women, 
with most items showing no change,  apart from:
Mean On tamoxifen  3 months later  Change? 
Global QoL  79.5  76.6  NS 
Role Function 92 88  p = 0.05
Social Function 93.7  90.6  p = 0.01
Fatigue  14.4  20.6  p = 0.003 
Median score (1 – 7) 
Nausea/Vomiting  4.7  2.2  p = 0.05
These data suggest that there is a low level of GI toxicity associated 
with tamoxifen, and some loss of social functioning associated with 
stopping it.  Larger studies are required to see if there is a subgroup 
of patients who need additional support after stopping tamoxifen. 
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BAG-1 POTENTIATES OESTROGEN DEPENDENT 
TRANSCRIPTION AND PROTECTS BREAST CANCER
CELLS FROM STRESS-INDUCED GROWTH 
INHIBITION
Graham Packham*, RamseyI Cutress, Paul A Townsend,
AdamSharp and Peter WM Johnson.
Cancer Research UK Oncology Unit, Cancer Sciences 
Division, School of Medicine, Universityof Southampton, 
Southampton General Hospital, Southampton, SO16 6YD.  
  BAG-1 is a multifunctional protein which exists as three 
isoforms, BAG-1S, BAG-1M and BAG-1L. BAG-1 proteins 
interact with a diverse array of cellular targets and regulate a 
wide range of cell growth control pathways including 
survival, proliferation and the function of some nuclear
hormone receptors. Overexpression of BAG-1 has been
described in breast cancer where it may predict clinical 
outcome.  However, the functional significance of BAG-1 
overexpression has not been studied in detail. 
Overexpression of BAG-1 has profound effects on the 
biology of breast cancer cells.  BAG-1L, which resides in the 
nucleus, interacted with oestrogen receptor alpha and 
stimulated oestrogen dependent transcription.  All BAG-1 
isoforms protected breast cancer cells from apoptosis and 
long term growth inhibition induced by cellular stress.  
Suppression of stress-induced growth inhibition required a 
conserved lysine in the BAG-1 N-terminal ubiquitin-like 
domain and C-terminus residues important for interaction 
with 70 kDa heat shock proteins, HSC70 and HSP70.  
Therefore, overexpression of BAG-1 is likely to play an 
important role in breast cancer and targeting key
protein:protein interactions required for its function may be
an attractive strategy to counter its activity.
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VITAMIN D RECEPTOR SIGNALLING IS CORRUPTED IN
BREAST CANCER CELLS VIA A HISTONE DEACETYLATION
MECHANSIM
Claire M. Banwell, Laura P. O’Neill & Moray J. Campbell; Division of
Immunity and Infection, Medical Sciences, Univ. Birmingham, B15 2TH 
   The intrinsic ability of 1α,25 dihydroxyvitamin D3 (1α,25(OH)2D3) 
to control the proliferation of breast epithelial cells is corrupted in 
malignancy thus  impeding its clinical application.  We hypothesised 
that epigenetic mechanisms suppress antiproliferative target genes in 
1α,25(OH)2D3-insensitive breast cancer cells. In support of this we 
found that resistance to the antiproliferative actions, in a range of 
malignant breast cell lines (T-47D, ZR-75-1, MCF-7, MCF-7Res and 
MDA-MB-231) and the non-malignant breast epithelial cells MCF-
12A cells, correlated with significantly reduced vitamin D receptor
(VDR) and increased nuclear receptor co-repressor mRNA.
      Subsequently we demonstrated that the histone deacetylation 
inhibitors sodium butyrate (NaB) and trichostatin A (TSA) showed 
strong additive and synergistic antiproliferative effects when 
combined with 1α,25(OH)2D3 or its potent analogs that were 
resistant to metabolism. For example, after 96 hours, 1,25-
Dihydroxy-16,23,Z-diene-26,27-hexafluoro-19-nor vitamin D3 (RO-
26-2198) (100nM) alone inhibited MDA-MB-231 cells by 13%, 
TSA (15nM)  resulted in 26%, and the combination resulted in 61% 
inhibition (p<0.001). Reflective of this the co-treatment alone 
resulted in a significant G1 cell cycle arrest after 24 hours. Consistent 
with the hypothesis of repressed antiproliferative target genes, we
undertook real time RT-PCR time course studies to confirm that the 
co-treatment of agents uniquely modulated antiproliferative targets 
such as the CDKI p21
(waf1/cip1) and the metastasis suppression gene 
VDUP-1. Furthermore preliminary data suggests that the co-
treatment of agents sustains bulk histone acetylation. Thus combined 
chemotherapy with 1α,25(OH)2D3  analogs and clinically relevant 
HDAC inhibitors may deliver therapeutic regimes, which overcome
toxic side-effects and sustain anticancer effects. 
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CHARACTERISATION OF DOCETAXEL RESISTANT
BREAST CANCER CELL LINES
Sarah L. McDonald*, Susan E. Moir, Ahmed O. Babalghith,
David A. J.Stevenson, Steven D. Heys, Heather M. Wallace,
Andrew. C. Schofield.  Depts. of Surgery, Molecular and Cell
Biologyand Medicine and Therapeutics.  University of 
Aberdeen, AB25 2ZD. Scotland.   
Docetaxel is one of the most effective chemotherapy agents 
used to treat advanced breast cancer.  Unfortunately, many
patients develop resistance to treatment and the resistance
pathways are largely unknown.  In order to investigate the 
mechanisms involved we have developed docetaxel resistant 
MCF-7 and MDA-MB-231 cell lines.  The aims of the project 
were to characterise the resistant cell lines and to identify novel 
regions of genomic change involved in resistance to docetaxel
using Comparative Genomic Hybridisation (CGH). 
The docetaxel resistant cell lines were generated by sequential 
exposure to docetaxel.  Resistance was demonstrated by MTT 
assay.  Genomic changes between the parental cells and the 
resistant sub-line was investigated by CGH.  Western analysis 
was used to demonstrate changes in protein expression. 
Exposure to increasing concentrations of docetaxel for 50 
weeks resulted in cells able to withstand 24 h exposure of 30 µM 
docetaxel.  Western analysis revealed that the resistant cells 
overexpress P-glycoprotein.  In addition, CGH showed a large 
amplification of 7q21.3-7q31.1 in the MCF-7 resistant subline. 
This is the first description of the use of CGH to identify genes 
involved in docetaxel resistance. Further investigation of these 
cell lines will lead to a better understanding of the mechanisms
of resistance and ultimately may result in the development of 
more effective therapy.
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BCL-2 OVEREXPRESSION IN A DOCETAXEL RESISTANT 
BREAST CANCER CELL LINE.
Iain Brown*, Sarah L McDonald, Susan E Moir, Steven D Heys,
Andrew C Schofield.  
Dept. of Surgery, Medical School, University of Aberdeen. 
 Introduction:  Docetaxel is the most effective single agent 
regimen in advanced breast cancer therapy.  However, up to 50% 
of patients are resistant to the disease.  There may be many
reasons why a tumour may be resistant to chemotherapy including 
innate and acquired resistance mechanisms. 
Aims:  There is limited data on molecular factors involved in 
resistance to docetaxel.  We sought to determine, therefore, the 
molecular changes in breast cancer cell lines which had been 
made resistant to docetaxel in order to further understand the 
mechanisms of resistance to this drug. 
 Methods:   MCF-7 cells were made resistant to docetaxel by
continual exposure to increasing amounts of the drug over a 
period of time.  We looked at the levels of expression of proteins 
expected to be involved in apoptosis or resistance (P-
glycoprotein, bcl-2, bax, p53, mdm2, p16) by western analysis in 
resistant and wild-type cells. 
Results:  Docetaxel resistant cells overexpressed bcl-2 and p-
glycoprotein compared to wild-type cells which had no detectable 
levels of each protein.  p16, bax and p53 levels were unchanged. 
No mdm2 was detected in either cell line. 
Significance and conclusion:  It is known that bcl-2 expression 
is upregulated in response to docetaxel treatment, but this is the 
first time it has been shown to be permanently upregulated in a 
resistant cell line.  It is likely that there is more than one 
mechanism of resistance other than p-glycoprotein overexpression 
in these cells and we are currently looking at other apoptosis, cell 
cycle, and drug metabolism pathways, in these and another 
resistant cell line, to further understand these mechanisms. 
Poster Presentations
S59
British Journal of Cancer (2003) 88(Suppl 1), S55–S72 & 2003 Cancer Research UKP139
DIINDOLYLMETHANE INDUCES APOPTOSIS AND
INHIBITS PKB/AKT PHOSPHORYLATION IN THE MDA
MB468 BREAST TUMOUR CELLLINE
Mark J Anderton*, Lynne M Howells, E Ann Hudson, William P
Steward, Margaret M Manson, Biocentre and Dept. of Oncology,
University of Leicester, UK
Diindolylmethane (DIM) is a major in vivo derivative of the 
anticancer agent indole-3-carbinol (I3C). We showed previously
that I3C induces apoptosis in the MDA MB468 breast tumour cell 
line but not in the normal breast tissue derived HBL100 line. This
effect was in part due to the ability of I3C to inhibit 
phosphorylation and activity of protein kinase B (PKB/Akt) in the 
MDA MB468 cell line only. In the present study we compared the 
ability of DIM with that of I3C to inhibit cell growth and induce 
apoptosis in these two cell lines. DIM was a more potent inhibitor 
of cell growth with approximate IC50 values (at 168 hr) in MDA
MB468 and HBL100 cell lines of 5 and 40 µM respectively,
compared to 30 and 120 µM for I3C. Like I3C, DIM was able to 
induce apoptosis in the MDA MB468 cell line as determined by
annexin V staining, but again showed greater potency, with 50 µM 
DIM causing a similar degree of apoptosis as 200 µM I3C at 24 
and 48 hrs (10 and 45 % respectively). Using Western blotting, 
DIM was shown to inhibit phosphorylation of PKB, more quickly
and with a higher potency than I3C. After 5 hrs, 100 µM DIM 
inhibited PKB phosphorylation by approximately 50%, a degree of 
inhibition that required 500 µM I3C. Neither compound affected 
total PKB protein levels. Inhibition of PI3K/PKB signalling may
therefore be an important chemopreventive mechanism of DIM. In 
conclusion, DIM showed considerably greater potency and more 
rapid activity than its parent compound, and is an exciting prospect 
as a chemopreventive agent. 
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EXPRESSION OF HUMAN DELTA-6-DESATURASE AND
DELTA-4-DESATURASE IN HUMAN BREAST CANCER AND
THE ASSOCIATION WITH CLINICAL OUTCOMES.  Jane Lane,
Robert E. Mansel, Wen  G. Jiang.  Metastasis Research Group.
University Department of Surgery, University of Wales College of
Medicine, Heath Park, Cardiff, The United Kingdom 
 
Highly unsaturated fatty acids (HUFAs) are cytotoxic to cancer cells 
and generated in the body by desaturation from essential fatty acids 
such as alpha-linolenic acid and linoleic acid. The desaturation is 
primarily mediated delta-6-desaturase. This study, for the first time, 
examined the level of expression of human delta-6-desaturase as 
well as delta-4-desaturase in human breast cancer. Human breast 
tumours (n=102) which comprised of 88 ductal and 14 lobular 
carcinomas, as well as normal breast tissues (n=31), together with 
breast cancer cell lines were analysed for the level of expression of 
delta-6- and delta-4-desaturases using RT-PCR and quantitative 
PCR. A lower level of delta-6-desaturase was seen in breast tumour 
compared with normal tissues. Tumours from patients who had a 
poor prognostic index and from those who died of breast cancer had 
the lowest level of delta-6-desaturase (median follow-up 72 months). 
In addition, TNM3 and TNM4 tumours had significantly lower level 
of delta-6-desaturase than TNM1 tumours. Interestingly, ductal 
tumours displayed significantly higher level of the enzyme than 
lobular tumours. In contrast, a stepwise increase of delta-4-
desaturase was seen in tumour from patients with poor prognosis. It 
is concluded that aggressive breast tumours have a reduced level of 
delta-6-desaturase. This aberrant expression has clinical bearings to 
the outcome in patients with breast cancer. 
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DEVELOPMENT AND CHARACTERISATION OF AN IN
VITRO CELL MODEL OF TAMOXIFEN-RESISTANCE.
Alicia Parkes*, Sarah Burdall, and Valerie Speirs.  Molecular
Medicine Unit, University of Leeds, Leeds, LS9 7TF. 
Tamoxifen (TAM) is an established adjuvant treatment for 
hormone-dependent breast cancer and more recently in the 
prevention of the disease in high-risk individuals.  Despite its 
success, the majority of initially responsive patients (60-70%) 
eventually relapse. The aim of this study was to develop and 
characterise an in vitro model of resistance using the TAM-
sensitive breast cancer cell line MCF-7, by continuous culture in 
0.1µM 4-Hydroxy-Tamoxifen (4-HT) over 28 months.  Cell 
phenotype and response to ER ligands was monitored as 
resistance developed, on a monthly basis. Cytogenetic analysis is 
on-going. wtMCF-7 express ERα, -β, and PR and were initially
inhibited by 4-HT by 50% over controls.  By flow cytometry,
cells in S-phase were also significantly reduced.  By month 4 the 
inhibitory effect of TAM was lost, indicating the acquisition of 
resistance (MCF-7r).  This effect was consistent up to 28 months. 
In comparison to wtMCF-7, MCF-7r grew more slowly (30% less 
than wt). Upon removal of TAM, the resistant phenotype was 
retained, although addition of 0.1nM 17β-estradiol (E2) had an 
agonistic effect. In the continued presence of TAM, the effect of 
E2 was concentration-dependent: agonistic at 0.1nM E2, but 
antagonistic below 0.01nM, suggesting a competitive interaction 
between the two compounds. ERα, -β and PR were retained in 
MCF-7r indicating a functional ER-signalling pathway. Using a 
clonogenic assay, 6 individual clones were isolated from MCF-7r. 
These retain resistance to TAM but show differences in 
morphology and in vitro growth. This cell line model will be 
valuable in understanding the mechanisms involved in the 
acquisition of TAM-resistance. 
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DETERMINATION OF MICROVESSELS IN HUMAN BREAST
CANCER USING VASCULAR ENDOTHELIAL CADHERIN (VE-
CADHERIN)
Tracey A. Martin*, Gareth Watkins, Jane Lane, Wen Guo Jiang. Metastasis
Research Group, Department of Surgery, UWCM, Cardiff, CF14 4XN.
     VE-cadherin is a calcium-dependent endothelial-specific cell adhesion 
molecule associated with adherens junctions. Cadherin expression is believed to 
facilitate morphogenic events such as migration, proliferation, and 
differentiation.
     This study aimed to determine if VE-cadherin could be used as a suitable 
marker to assess angiogenesis and whether a correlation exists between levels of 
VE-cadherin and angiogenic markers Factor-8 & PECAM-1 with patient 
outcome in breast cancer. Frozen sections from breast cancer primary tumours 
(matched tumour n=114, & background n=30) were immuno-stained with VE-
cadherin, Factor-8 and PECAM-1 antibodies and microvessel number assessed. 
RNA from the tissues was reverse transcribed and quantified before analysis by 
Q-PCR.  VE-cadherin, Factor-8 and PECAM-1 were targeted as angiogenic 
markers. Results were expressed as copy numbers of transcript/50 ng RNA (β-
actin standardised).
    Immunohistochemical staining for all three markers showed a significant 
difference in microvessel number in tumour sections compared to background 
with VE-cadherin (background: 7.29 +/- 0.77 vessels vs tumour 17.56 +/- 1.5, 
p=0.0008). There was no significant difference in the number of microvessel 
stained with either PECAM-1 (background 2.08+/-0.78 vs tumour 2.36+/-0.25, 
p=0.75) or Factor-8 (background 59.8+/-12 vs tumour 49.4+/-4.7, p=0.43) where 
there was increased staining of other structures within the sample and higher 
background. In addition, Q-PCR showed elevated levels of VE-cadherin and 
PECAM-1 in tumour samples compared to background tissue (VE-cadherin: 
tumour 2.356+/-0.64 vs background 1.979+/-0.613 p=0.7; PECAM-1: tumour 
275+/-73.7 vs background 145.7+/-30 p=0.8). These markers were also elevated 
in patients with poor prognosis, as determined by NPI status (VE-cadherin: 
NPI3 7.3+/-4.8 vs NPI1 2.25+/-0.697; PECAM-1: NPI3 814+/-519 vs NPI1 
256.2+/-89.2). There was no difference in levels with Factor-8.
    We conclude that higher levels of angiogenic marker molecules in breast 
cancer are associated with poor prognosis in patients. Moreover, VE-cadherin 
appears to be a preferable marker for such analysis. 
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A PHASE 2 STUDY OF CHLORAMBUCIL AND LOMUSTINE
(CL56) IN THE TREATMENT OF ABSOLUTE HORMONE
REFRACTORY PROSTATE CANCER
Gairin Dancey*, Jonathan Shamash, Pompa Bhattacharyya, Peter
D. Wilson, Lynda J. Millard and R.Timothy D.Oliver. Department
of Medical Oncology, St Bartholomew’s Hospital, London. 
  The last two years has seen an increasing interest in the use of 
chemotherapy for prostate cancer using combinations of 
estramustine and  iv docetaxel. In this elderly population the
potential benefit of a simple oral regimen was explored. 37 patients 
(33 symptomatic) with a median age of 71 and performance status 
of 0-3 were enrolled. All patients had previously had second line 
hormonal therapy with a steroid and an oestrogen. On progression, 
hormones were withdrawn and chlorambucil 1mg/kg, given as 
6mg a day until total dose reached and lomustine 2mg/kg on day 1 
were given and repeated every 56 days (CL56).  
Results:1 patient normalised his PSA and 3 had > 50% decline 
to give a PSA response rate of 10%. 65% achieved disease 
stabilisation beyond 8 weeks and 54% had a symptomatic 
response. The median time to progression was 3.6 months (4.6 
months in those with ≥ SD, vs 1.2 months in those with PD, 
p<0.05) with an overall survival of 7.1 months. Toxicity was mild
with grade 3 toxicity of malaise 14% and constipation 12%. The
median survival from becoming androgen independent was 23.5 
months. 4/15 who progressed on chemotherapy responded again to
hormonal manipulation when rechallenged. It is concluded that the 
sequential use of androgen deprivation, followed by steroids and 
oestrogens and then chlorambucil and lomustine leads to 
comparable survival to the current estramustine and taxane based 
therapies.
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NEP AND ECE CAN MODULATE STROMAL-EPITHELIAL
INTERACTIONS AND CAN INFLUENCE INVASIVE
BEHAVIOUR OF PROSTATE CANCER CELLS 
Louise A Dawson*
1, Norman J Maitland
2, Anthony J Turner
1, Badar 
A Usmani
1 
1School of Biochemistry & Molecular Biology, University of Leeds, 
Leeds LS2 9JT; 
2 YCR Unit, Dept. of Biology, University of York 
YO10 5YW 
 
The structurally related metalloproteinases endothelin-converting-enzyme 
(ECE) and neprilysin (NEP) contribute respectively to the synthesis and 
inactivation of the mitogenic peptide endothelin-1 (ET-1). Changes in a 
developing tumour during stromal-epithelial interactions can contribute to 
cancer invasion and metastasis as a consequence of the availability of 
endothelin-1. This study has investigated the interaction between metastatic 
tumour epithelial cells which lack NEP and stromal cells which express ECE-1, 
using Matrigel invasion chambers. Data show that PC cell invasion through 
Matrigel is increased in the presence of ECE-1 expressing stromal cells. 
Inhibition of endogenous ECE-1 activity in stromal cells using an ECE specific 
inhibitor reduced PC-3 and Du145 invasion by ~70% and 50% respectively. 
Inactivation of mitogenic peptides by the addition of recombinant NEP to PC-3 
and Du145 cells also reduced invasion by ~50% and 20% respectively. 
Alternatively, supplementation of defined media with bradykinin and ET-1 
significantly increased PC-3 invasion by ~40% and 50% respectively. Du145 
cell invasion increased 100% on the addition of ET-1. Transient expression of 
an ECE-1c isoform in PC-3 cells increased invasion above control by ~15%, 
whereas transient expression of ECE-1a and ECE-1b isoforms reduced invasion 
by 40% above control. ECE-1a and ECE-1b isoforms are routinely absent in 
metastatic cells. These studies reveal that stromal/epithelial interactions can 
influence the invasive ability of PC cells partly as a consequence of their 
relative NEP and ECE-1 activity and this effect may be attributed to the ECE-1c 
isoform in particular. 
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SERUM PROSTATE SPECIFIC ANTIGEN (PSA)-NEGATIVE
METASTATIC PROSTATE CANCER:HISTOPATHOLOGY
AND AN ALTERNATIVE DIAGNOSTIC MARKER. 
Alison J.Birtle* Alex Freeman,Stephen J.Harland, 
Heather A.Payne & John R.M.Masters.Prostate Cancer Research  
Centre,67,Riding House St, London.W1W 7EJ.  
   Approximately 1% of men present with "PSA-Negative"  
prostate cancer (PCA), having serum PSA levels much lower  
than the tumour burden would suggest. Diagnosis and  
treatment can be delayed, and PSA levels are unreliable in  
monitoring disease. Alternative markers are needed  
for diagnosis and surveillance. We describe the  
histopathological features and marker expression of 14
prostate cancers from men presenting with metastatic
disease and low PSA.    Patients presenting with metastatic
PCA, with serum PSA of less than 10 ng /ml were identified  
from the BAUS Cancer Registry. Formalin  
fixed, paraffin-embedded archival prostatic tissue was  
antigen retrieved and immunostained using monoclonal
antibodies for PSA, prostate specific membrane antigen  
(PSMA), prostate specific acid phosphatase (PSAP), androgen  
receptor and neuroendocrine markers. Semi-quantitative  
scoring was performed.14 cases have been analysed. Despite low serum
PSA levels, focal tissue staining for PSA was seen in 11/ 14  
cancers. PSMA staining was observed in all cancers, with a  
diffuse pattern and was present in cancer cells negative  
for PSA in 9 / 14 cases. Androgen receptor staining was  
positive in 12/14 and PAP in 10/14 cases. 7 cases were  
weakly positive for neuroendocrine markers. Median Gleason  
score was 9. PSMA is diffusely present in prostatic
tissue in serum "PSA-Negative" metastatic PCA patients.
Focal tissue staining for PSA may easily be missed on  
biopsy. PSMA can aid histopathological diagnosis of  
prostate cancer in patients presenting with clinical signs
of metastatic PCA and low serum PSA. Significant  
neuroendocrine differentiation was not a feature. 
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IS INCREASED LIPID PEROXIDATION IN PATIENTS WITH
PROSTATE CANCER DUE THE SYSTEMIC
INFLAMMATORY RESPONSE OR INSUFFICIENT
INTAKE?
Ahmad  Almushatat*, Donald C McMillan, Dinesh Talwar,Peter A 
McArdle, Naveed Sattar, Denis StJ O’Reilly, Mark A Underwood 
Introduction
Patients and methods
Results
Conclusion  
    Oxidative stress is recognised to contribute to the nutritional decline of 
cancer patients. The basis of this oxidative stress could either be due to the 
tumour itself or a host response. The polyunsaturated fatty acid residues 
of phospholipids are extremely sensitive to oxidation. The major product 
of lipid peroxidation is malondialdehyde (MDA). To determine whether 
oxidative stress was due to the presence of cancer, the systemic 
inflammatory response or insufficient intake of antioxidants, we examined 
the relationship between lipid peroxidation (MDA), lipid soluble vitamins 
(α-tocopherol and carotenoids), host systemic inflammatory response (C-
reactive protein) and stage of disease in patients treated for prostate cancer. 
    Patients with BPH (n=19), localised (n=32) and metastatic (n=39) 
prostate cancer were studied. Blood samples were removed for the 
measurement of PSA, CRP, MDA, cholesterol, α-tocopherol, lutein, 
lycopene, α–carotene, and β-carotene. MDA concentrations were adjusted 
for cholesterol. The study was approved by the local ethics committee.
    Increased MDA concentrations were associated with more advanced 
stage of disease and reduced lutein and lycopene concentrations.  In 
contrast, there was no significant alteration in the other lipid soluble 
vitamins or C-reactive protein 
    Lipid peroxidation and reduced carotenoid concentrations appear to be 
dependent on stage of disease but not the low grade systemic inflammatory 
response in patients with prostatic disease.  This would suggest that there is 
insufficient dietary intake of carotenoids for the oxidative stress associated 
with the presence of prostate cancer. 
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DEXAMETHASONE AS AN ALTERNATIVE TO CORTISONE OR 
HYDROCORTISONE IN COMBINATION WITH STILBOESTROL FOR 
HORMONE REFRACTORY PROSTATE CANCER
Madhumita Bhattacharyya*, Garin Dancey, Peter Wilson, Wendy Ansell, 
Jonathan Shamash, Tim Oliver, J Ong, Medical Oncology, Barts and the 
London Medical School
Introduction and Aim:
    Farrugia et al 1998 observed a high PSA response rate (78%) when 
Stilboestrol + hydrocortisone were given to patients with hormone 
refractory prostate cancer. Reports suggesting Dexamethasone was more 
effective than hydrocortisone as a single agent in these patients lead to a 
phase 2 study to evaluate Stilboestrol + Dexamethasone (S+D). This abstract 
reviews these results and compares them with updated results from use of 
Stilboestrol + other corticosteroids (S+C/HC).
Procedure:
 M+ or M0 symptomatic with rising PSA on > 1 occasion while receiving 
primary endocrine treatment were selected. Stilboestrol 1mg, 
Dexamethasone 2mg + aspirin 75mg were given daily. In the previous 
protocol patients received hydrocortisone 20mg bd or cortisone acetate 
25mg o'mane and 12.5mg o'nocte
Results:
 73 patients treated with S+C/HC, 41 with S+D. Median time to going off 
study was 15.2 months after S+C/HC v 13.5 after S+D. At 2 years 16% on 
S+ C/HC and 20% on S+D remain on treatment. On progression, duration of 
response to Chlorambucil/Lomustine was 6.8 months in those who failed 
S+C/HC and 8.8 months S+D. 50% PSA response rate, was 73% on S+ 
C/HC and 78% on S+D. Though toxicity was similar, Dexamethasone 
produced more fluid retention.
Conclusion:
 Despite the reported advantage of Dexamethasone over cortisone as single 
agent, there seems to be no major advantage of Dexamethasone when 
combined with Stilboestrol as an alternative to cortisone or hydrocortisone. 
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ANDROGENS INCREASE OXIDATIVE DNA ADDUCT 
LEVELS IN HUMAN PROSTATE CELLS
SK Pathak*, RA Sharma, R Singh, PB Farmer, WP Steward, AJ 
Gescher, JK Mellon.  Departments of Oncology, Urology & 
Biochemistry, University of Leicester, Leicester LE2 7LX, UK. 
    Reactive oxygen species involved in carcinogenesis have been 
shown to attack DNA bases. Two adducts arising from oxidative 
DNA damage are 8-oxo-deoxyguanosine (8-oxo-dG) and 
pyrimidopurinone adducts of deoxyguanosine (M1G).  Both adducts 
have been associated with mutagenesis and carcinogenesis. 
Dihydrotestosterone (DHT) causes oxidative stress in androgen-
sensitive human prostate cancer cells, but its effect on oxidative 
DNA adducts has not been studied.  We tested the hypothesis that 
DHT increases levels of oxidativeDNA adducts in androgen-
sensitive LNCaP cells. We also studied its effect in androgen-
insensitive PC3 and DU145 cells.  8-Oxo-dG levels were measured 
by LC-MS/MS with correction for amount of DNA by HPLC-UV, 
and M1G levels by immunoslot blot with correction by propidium 
iodide staining. Mean 8-oxo-dG levels in control LNCaP, PC3 and 
DU145 cells were 2.9, 3.5 and 4.1 adducts/106 nucleotides 
respectively, and M1G levels were 12.6, 6.9 and 7.5 
adducts/107nucleotides respectively.  M1G levels in DHT-treated 
LNCaP, PC3 and DU145 cells were 17.2, 7.9 and 7.4 adducts/107 
nucleotides respectively, and 8-oxo-dG levels were 4.9 adducts/106 
nucleotides in LNCaP cells. The difference in adduct levels between 
control and DHT-treated cells was significant only for M1G levels in 
LNCaP cells (P < 0.05 by ANOVA).   The results represent the first 
report of measurable oxidative DNA adducts in human prostate 
cancer cells grown in vitro and suggest that androgens can increase 
M1G levels in androgen-sensitive cells.
    Supported byUK MRC and Prostate Research Campaign UK.  
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HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR REGULATES 
THE EXPRESSION OF HGF ACTIVATION REGULATORS, HAI-1 AND 
MATRIPTASE-1, IN HUMAN PROSTATE CANCER CELLS.
Rhidian A. Hurle1, Chris Parr1, Spencer A. Jenkins2, Howard G. Kynaston2, 
Wen G. Jiang1.  1Metastasis Research Group, University of Wales College of 
Medicine, and 2Department of Urology, University Hospital of Wales, Cardiff 
CF14 4XN, UK.
Hepatocyte growth factor (HGF), otherwise known as scatter factor (SF), is a 
cytokine that plays an active role in the migration and invasion of cancer cells, 
including prostate cancer cells. This study examined the role of HGF on the 
expression of HGF activators, Matriptase-1 and HGFA, and HGF activation 
inhibitors HAI-1 and HAI-2 in human prostate cancer cells.
A non-invasive human prostate cancer cell line, CA-HPV-10 and a highly 
invasive line PC-3 were used in the study. Cancer cells were treated with 
recombinant human HGF for periods upto 24 hours. The mRNA levels of 
HAI-1, HAI-2, HGFA and matriptase-1 were determined using RT-PCR and 
quantitative PCR, with β-actin as control house keeping gene. The protein 
levels of these molecules were assessed using Western blotting from cells 
similarly treated with HGF. HGF increased the transcript levels of matriptase-
1 in PC-3 cells (Threshold cycle No. 42.6±1.02 in control and 35.6±0.39 in 
HGF treated cells, p<0.01). The effect of HGF on matriptase-1 in CA-HPV-10 
cells was, however, insignificant (Threshold cycle No. 37.9±0.32 in control 
and 38.3±1.4 in HGF treated cells, p=0.38). In contrast, HGF increased the 
levels of expression of HAI-1 in both cells, with the most profound effect seen 
in CA-HPV-10 cells (39.1±6.5 vs 34.7±1.6 in CA-HPV cells and 33.7±0.8 vs 
32.4±0.3 in PC-3 cells). The effect of HGF on the levels of expression of 
HAI-2 was inconclusive. It was further revealed that the changes in mRNA of 
HAI-1 in prostate cancer cells were reflected at protein level. Western blotting 
showed an increased amount of HAI-1 protein in HGF-treated cells compared 
with untreated cells.
It is concluded that hepatocyte growth factor has direct effect on the molecules 
that regulates the activation of pro-HGF, such as HAI-1 and matriptase-1 and 
that HGF may have a wider role in its action on prostate cancer cells.  
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POTENTIATION OF RADIOTHERAPY BY THE EGFR 
TYROSINE KINASE INHIBITOR ZD1839 (IRESSA) ON 
BLADDER CANCER  IN VITRO. 
Satish B. Maddineni*
1, Vijay Sangar
1, Geoff P. Margison
1, Jolyon 
H. Hendry
1, Kieran J. O’Flynn
2, Noel W. Clarke
2,3. 
1Carcinogenesis Group, Paterson Institute for Cancer Research, 
Manchester, 
2Salford Royal Hospitals NHS Trust, Salford,
 3Christie 
Hospital NHS Trust, Manchester, UK. 
 
Introduction: Radiotherapy is an established organ preserving 
radical treatment for invasive bladder cancer. Enhancing the 
response to ionising radiation (IR) may further improve prognosis. 
We established the radiosensitising properties of ZD1839 on 2 
related bladder cancer cell lines of differing radiosensitivities. 
Methods:  The radiation survival curves for MGH-U1 
(radioresistant) and its mutant clone S40b (radiosensitive) were 
established using clonogenic assays. ZD1839 was added for 24 
hours prior to IR (0-10Gy). Data was analysed using unweighted 
non-linear least squares regression. Cell cycle kinetics and 
apoptosis were analysed using PI staining, Annexin-V FITC 
conjugates and flow cytometry. 
Results:  ZD1839 alone exhibited no growth inhibitory effect 
(p=0.9). The survival fraction at 2Gy (SF2) was 0.88 and 0.66 for 
MGH-U1 and S40b respectively (p<0.001). With ZD1839 the SF2 
and SF10 values were 0.83 and 0.012 for MGH-U1 and 0.42 and 
0.0079 for S40b (p<0.001) consistent with a significant 
radiosensitising effect. No significant alteration in cell cycle 
kinetics was demonstrated. ZD1839 had a modest pro-apoptotic 
effect that was significantly enhanced in combination with IR. 
Conclusion: ZD1839 enhanced anti-tumour potentiation of IR in 
bladder cancer cells. This was associated with a significant 
induction of apoptosis. This radiosensitising effect may have 
promising clinical implications for future treatment. 
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A PHASE I TRIAL OF INTRA-VESICAL GEMCITABINE IN 
THE TREATMENT OF RECURRENT SUPERFICIAL 
TRANSITIONAL CELL CARCINOMA OF THE BLADDER. 
Satish B. Maddineni*
1, Vijay Sangar
1, Christopher D.Betts
1,Kieran 
J. O’Flynn
1  & Noel W. Clarke
1,2. 
1Salford Royal Hospitals NHS Trust, Salford, 
2The Christie 
Hospital NHS Trust, Manchester, UK. 
Introduction: Superficial transitional cell carcinoma (TCC) 
accounts for 70-80% of all bladder cancer and has a high risk of 
recurrence and histological progression. Post-resection 
chemotherapy reduces recurrence by up to 50%. Systemic 
Gemcitabine is an active agent in bladder cancer. The aim of this 
study is to determine the maximum tolerated dose (MTD) and 
dwell time of intra-vesical Gemcitabine in patients with recurrent 
superficial TCC  within 24 hours of trans-urethral resection. 
Methods: Patients with recurrent superficial TCC of the bladder 
(G1-3pTa or G1-2pT1) received intra-vesical Gemcitabine 
instillations at a dose of 5mg/ml in 100ml NaCl with dwell times 
of 1 and 2 hours. Each dose level was studied in cohorts of 3 
patients. Dose was escalated in 500mg increments. Patients 
underwent cystoscopy under general anaesthetic at 3 months. 
Results:  16 patients have been studied with a mean age of 75 
years. The 5mg/ml dose level was tolerated for both dwell times 
with no significant toxicity. 4 patients were studied at the 10mg/ml 
dose level but the maximum tolerated time to micturition was 40 
minutes. Volume for dilution was reduced to 50ml of NaCl. 3 
patients have been treated with a 1000mg in 50 ml of NaCl 
(20mg/ml) at both dwell times with no adverse effects. 
Conclusion: Intra-vesical Gemcitabine is tolerated at 1000mg in 
50ml of NaCl post-resection. Further studies are planned to assess 
this regional treatment as an adjuvant therapeutic option in the 
treatment of superficial carcinoma of the bladder. 
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A TARGETED RADIOTHERAPY/GENE THERAPY 
STRATEGY FOR BLADDER CANCER  
Natasha Fullerton, Marie Boyd, *Lesley Wilson, Nicol Keith, 
David Kirk and Robert Mairs  
Dept. of Radiation Oncology, Cancer Research UK Beatson 
Laboratories, Glasgow. 
Targeted radiotherapy is the selective irradiation of tumour cells 
byradionuclides conjugated to tumour-seeking molecules. One such 
molecule, radiolabelled MIBG, is actively taken up via the 
noradrenaline transporter (NAT) only by tumours of 
neuroectodermal origin.  Our aim  was  to apply this targeted 
radiotherapy to bladder cancer by gene transfer and  limit  NAT 
gene expression to bladder cancer cells by using a tumour specific 
telomerase promoter  
The human bladder cancer cells, EJ138, were transfected with the 
NAT gene under control of the CMV, hTERT and hTERC 
promoters, exhibited a 11-, 34- and 36-fold enhancement, of  active 
uptake of [
131I]MIBG. Administration of [
131I]MIBG resulted in 
dose dependant cell kill  of EJ138 cells transfected with the NAT 
under control of the telomerase and CMV promoters. 
Biodistribution studies 48hours post injection of [
131I]MIBG into 
mice bearing tumour xenografts  showed significantly increased 
uptake of [
131I]MIBG in the tumours derived from EJ138 
expressing NAT under the control of telomerase promoter 
compared to negligible uptake in parental EJ138 xenografts. 
These results show promise for a targeted radiotherapy / gene 
therapy approach for the treatment of  bladder cancer, which 
would decrease side effects in the form of radiation toxicity from
external beam irradiation and increase radiation dose to target 
organs, hence improving therapeutic efficacy.  
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A PHASE I/II STUDY OF GEMCITABINE AND CISPLATIN IN 
ADVANCED, METASTATIC, OR RELAPSED TCC OF THE BLADDER 
IN AN OUTPATIENT SETTING.  
Syed A. Hussain*,
1, 2 Deborah Stocken,
1 Peter Riley,
2 Ian Geh,
2 David 
Peake
2, David Spooner
2, Nicholas D. James,
1,2   Cancer Research UK Institute 
For Cancer Studies;
1 Queen Elizabeth Hospital,
2 Birmingham, United 
Kingdom. 
Introduction: A randomized phase III trial of MVAC vs. 
gemcitabine/cisplatin (GC) (G 1,000 mg/m
2 d1,8,15 plus C 70 mg/m
2 d2, q 4 
wks) indicated GC had similar efficacy and lower toxicity (JCO 2000). 
Significant hematologic toxicities in GC arm were on d15, causing dose 
adjustments in 37% of cycles.  We are conducting a phase I/II dose escalation 
trial with GC on a 21-day cycle, with G and C split between d1,8. 
Objectives: To define the MTD and toxicity; determine response, and 
progression-free and overall survival. Methods: 32 pts with locally
advanced, relapsed, or metastatic disease received: dose level 1: G/C 
1000/35; level 2: 1100/35; level 3: 1200/35; level 4: 1200/45 mg/m
2 (G and 
C given on d1,8 every 3 wks).  Eligibility: ECOG PS 0-2, adequate bone 
marrow/liver function, GFR > 40 mL/min.  Results: 32 pts enrolled; 28 
evaluable. Characteristics: M/F 22/10, median age 66 yrs (range 41-79), 
16/32 GFR < 60 mL/min. Stage: N+ (22), M1 (19). Prior therapy: cystectomy
(7); RT (8); progression after platinum-based chemo (3). DLT was 
hematologic (grade 4 thrombocytopenia) at level 2; study continued at level 
1. Hematologic toxicity: level 2 (9 pts): grade 4 neutropenia (2) and 
thrombocytopenia (3) were DLTs. Level 1 (23 pts): grade 3 anemia (4) and 
neutropenia (9), and grade 3/4 thrombocytopenia (10/2).  Nonhematologic 
toxicity: grade 1 perforation (1), grade 4 GI bleed (1) and acute abdomen (1), 
grade 3 nausea (2).  Of 125 cycles, platelets were <100 (d15) in 53; 
neutrophils <0.5, platelets <50 in 23. Only 3 cycles deferred due to grade 4 
neutropenia; 2 for renal toxicity (chemo instituted post hydration). 3 deaths 
occurred: 1 GI perforation (steroid antiemetic); 1 GI bleed (warfarin for DVT 
secondary to massive pelvic lymphadenopathy, ultimately found to have 
pyloric ulcer); 1 pt developed acute abdominal pain, and died after 
exploratory surgery. 1 pt was noncompliant. Overall ITT response was 68%
(79% [19/24] for assessable pts), with 4 CRs (14%) and 15 PRs (54%). 23 pts 
are alive, median follow-up 6.0 mos (range 1.0-18.1).  Survival analysis will 
be presented (12-mo minimum follow-up). Conclusion: G plus C every 3 
wks is active and well tolerated in an outpatient setting, even in pts receiving 
prior platinum-based regimens and with poor renal reserve. 
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LARGE CELL NEUROENDOCRINE LUNG CANCER: A 
DIFFERENT CLINICAL ENTITY? 
 
Marianne Nicolson and Keith Kerr on behalf of the Aberdeen 
Lung Cancer Group, ANCHOR Unit, Aberdeen Royal Infirmary, 
Aberdeen AB25 2ZN 
 
   Introduction: Large cell neuroendocrine carcinoma of the lung 
has recently been redefined by the World Health Organisation.   
These tumours share morphological characteristics with large cell 
carcinomas and immunohistochemical features with
neuroendocrine tumours. Clinically they behave more like small 
cell lung cancers and may require a different therapeutic approach.  
We present the data from 19 such patients (pts) diagnosed and 
treated between 1996 and 2002 in Aberdeen Royal Infirmary. 
   Method: Pathology listings were obtained for pts with large cell 
neuroendocrine cancers.  Notes review was undertaken to confirm 
that these were primary lung cancers. Data on treatment and 
survival are presented. 
   Results:  There were 12 males and 7 females. Age range was 42 
to 75 years. Stage at presentation was I/II 7 pts, IIIA 3 pts, IIIB 3 
pts and IV 6 pts.  Treatment was surgery in 10 (1 segmental 
resection, 5 lobectomy and 4 pneumonectomy), primary 
chemotherapy in 6, primary radiotherapy in 2 and 1 pt refused 
treatment. For the surgical pts, 2 of the 4 who had pneumonectomy 
are alive at 2 and 15 months out; two died at 14 and 15 months 
from disease relapse. Of the lobectomy pts, three relapsed at 9, 13 
and 18 months; follow-up data are incomplete on the other two and 
the one pt who had segmental resection. Of the patients with stage 
IIB and IV disease, one pt achieved CR maintained at 4 months, 
two had PR and three stable disease.  The updated survival of these 
patients and those treated with primary radiotherapy will be 
presented with a review of their pathology characteristics.  
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STROMELYSINS ARE DIFFERENTIALLY OVEREXPRESSED IN 
HUMAN LUNG CANCERS: POTENTIAL FOR THERAPEUTIC 
INTERVENTION  J M Seargent
1, P M Loadman
1, S W Martin
1, S
Tijani
2, J H Gill
*1. 
1Tom Connors Cancer Research Centre, University
of Bradford, UK; 
2Department of Histopathology, Bradford Royal 
Infirmary, Bradford, UK 
The degradation of the extracellular matrix (ECM) is central to tumour 
growth, invasion and metastasis. One class of enzymes responsible for 
such activities are the matrix metalloproteinases (MMPs), which 
include stromelysins 1 and 2 (MMP-3, -10). Knowledge of stromelysin 
1 and 2  (ST-1 and –2) expression in human lung carcinomas and their 
relationship to tumour characteristics is limited. Such information is 
likely to have both prognostic and diagnostic implications for human 
lung cancer. Understanding the expression profile of the stromelysins 
and their proposed tumour specific activity also has implications for the
development of selective anticancer drug development. This study
analysed ST-1 and –2 expression in human lung tumours of various 
grade, stage and type, initially to determine any relationship between 
expression and tumour characteristics and secondly to establish their 
potential as therapeutic targets. ST-1 and –2 protein expression was 
studied immunohistochemically using antibodies specific for either ST-
1 or ST-2. Formalin-fixed lung tumours from fifty patients representing 
all grades, stage, type and metastatic potential were studied. Consent to 
use these specimens in the current study was obtained from the relevant 
Local Research Ethics Committee. Differential tumour specific
expression of both ST-1 and ST-2 were observed in all cases. 
Expression of ST-2 was predominantly in the tumour epithelia whereas 
ST-1 was located primarily within the tumour stromal compartment. 
No correlation was observed between expression level and tumour 
grade or stage in either case. These data demonstrate that stromelysins 
1 and 2 are expressed in different tumour regions, demonstrate tumour 
specific expression and are valid targets for anticancer drug 
development.
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REDUCTION IN TESTICULAR GERM CELL CANCER SIZE 
WITH INCREASING AWARENESS. 
Jeetesh M Bhardwa*, RTD Oliver, Vinod  Nargund, D M  Berney 
  Improved overall survival of germ cell cancer was observed to be 
associated with increasingly early diagnosis and reduced tumour 
size
1. Over the last 6 years there has been considerable increase in 
public awareness of testis cancer. This abstract reviews trends in 
testis tumours size to see if there has been an impact of the 
increased awareness on tumour size. 
  Material & Methods: Pathology Department reports 
measurements in patients undergoing orchidectomy were reviewed 
and correlated with year of diagnosis. 
  Results: The median diameter of tumour size has reduced from 
24.5mm in 32 patients treated 1996 –98, to 19.5mm in 37 patients 
treated 1999 to 2002. 
Conclusion: These data confirm continuation of the trend 
previously observed when median fell from 48mm in 1978 –83, to 
45mm in 1984-85, 44mm in 1989-94
1 suggesting that improved 
health education in the susceptible male population had resulted in 
a reduction in testicular tumour size and this has implications for 
management of testicular tumour, such as use of testis conserving 
surgery and chemotherapy in patients with reduced germ cell 
function at presentation. 
Reference: Testis conservation studies in germ cell cancer justified 
by improved primary chemotherapy response and reduced delay, 
Oliver RT. Ong J. Blandy JP. Altman DG 1978-1994. [Journal 
Article] British Journal of Urology. 78(1): 119-24, 1996 Jul. 
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TREATMENT OPTION FOR MALIGNANT HEMANGIO- 
ENDOTHELIOMAS OF THE THYROID. 
Walter Rhomberg*, Franz Boehler, Helmut Eiter, Heinz Fritzsche, 
Gerhard Breitfellner. Correspondence: W.R., Department of Radio- 
oncology, General Hospital, A-6800 Feldkirch, Austria 
Background: Malignant hemangioendothelioma [MHE] of the 
thyroid is a rare tumour predominantly seen in areas with endemic 
goitre such as the Alpine regions. The tumour is regarded as radio- 
resistant and its prognosis is reported to be dismal (MST 2-4 
months) [Ladurner D et al (1990) Wien Klin Wochenschr 102:256].  
Patients and methods: Between 1982 and 1999, 12 cases with 
immunohistochemically confirmed MHE of the thyroid were 
referred for postoperative or palliative radiotherapy. By surgery, 
clear margins had been achieved in 5, microscopic residues were 
left in 3, and gross residual disease in 3 patients. One patient had an 
inoperable primary tumour. Postoperative radiotherapy between 54 
and 65 Gy was given to 8 cases, 6 of them received razoxane (125 
mg twice daily by mouth on radiation days). Razoxane is a radio- 
sensitizer and an agent which can normalize tumour blood vessels. 
Results: Local tumour control was achieved in 11 of 12 patients; 5  
of 12 lived longer than 5 years. The median survival time of all 
cases is 14 months. If 3 cases with a primary metastasis were left 
out from the analysis, the median survival is 70 months. The 
tolerance to the combined treatment was good to fair. 
Fibrinogen, factor VIII and factor VIII-antigen may eventually 
serve as „markers“ during the follow up. It may also be of interest 
that 5 of 12 patients were exposed to vinyl chloride and other poly- 
meric materials during their occupational life.  
Conclusions: The outcome of this disease may not be uniformly 
grim, and the resistance to radiotherapy reported in the literature 
may be questioned. Razoxane may have contributed to the high 
local control rate and thus perhaps to an alteration of the natural 
history of the disease to some extent.  
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A SMALL PROSPECTIVE STUDY OF CHORDOMAS 
TREATED WITH RADIOTHERAPY AND RAZOXANE.  
Walter Rhomberg*, Franz Boehler, Hansjörg Novak, Susanne 
Dertinger, Gerhard Breitfellner. *Dept. of Radiooncology, General 
Hospital, Carinagasse 47, A-6800 Feldkirch / Austria 
 
Purpose: To evaluate the local effect of conventional photon 
irradiation in chordomas if the radiosensitizing agent razoxane is 
added. The rationale for this procedure were low local control rates 
by photons (27%, textbooks), and improved responses previously 
seen in soft tissue and chondrosarcomas with photons + razoxane.  
Materials and methods: Between 1988 and 1996 five patients with 
histologically confirmed chordomas of the base of the skull or the 
spine (3 females, 2 males) were irradiated with high energy 
photons together with razoxane. The median total radiation dose 
was 63 Gy (range 54-67) with single fractions of 2 Gy. Razoxane 
was concurrently given at a dose of 125 mg twice daily by mouth 
on radiation days; the median total dose was 7.6 g per patient. The 
drug was started 3-5 days before the first irradiation. 
Results: After a potential median follow up time of 10 years, 3 of 
the 5 patients are alive and show neither symptoms nor signs of a 
recurrence in CT or MR images. One patient died after 8 years with 
a persistent sacral chordoma from cardiac insufficiency, and 
another patient died after 6.5 years from a haemorrhage after 
surgery for recurrence. All patients remained locally controlled for 
5 years and longer(5, 5.5+, 6.4, 11+ and 13+ years, respectively). 
Objective tumour regressions were noted in 3 of 4 patients with 
measurable disease. – Acute side effects were mucosal reactions, 2 
of 5 patients developed a leukopenia of grade 3 WHO due to 
razoxane. There were no serious long term complications. 
Conclusions: Although the patient series is small, there is an 
interesting trend in local control and survival. The cases are 
unselected, and the follow-up time is of considerable duration. The 
treatment is easy to perform at any institution. 
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STREPTOZOCIN, 5-FLUOROURACIL/FOLINIC ACID AND 
CISPLATIN (FCiSt) FOR ADVANCED NEUROENDOCRINE 
TUMOURS 
Debashis Sarker*¹, Martin Williams², John Buscombe³, Martyn 
Caplin 
4, Daniel Hochhauser¹, Richard Begent¹, Tim Meyer¹ Depts. 
of Oncology¹, Radiology², Nuclear Medicine³ and
Gastroenterology
4, Royal Free Hospital(RFH), London, NW3 2QG 
Background:  Streptozocin-based combination chemotherapy has 
become standard therapy for advanced neuroendocrine tumours 
(NET), particularly rapidly proliferating pancreatic NET. Cisplatin 
also has proven efficacy, in particular for poorly differentiated 
NET. At the RFH we have used a novel combination of these 
agents with 5-Fluorouracil (5FU) and Folinic Acid (FA). Patients 
and Methods: A retrospective review of 25 patients with advanced 
NET (14 pancreatic NET, 5 metastatic NET of unknown primary, 6 
metastatic carcinoid), from 1996-2003. Sites of metastatic disease 
were liver (14), locoregional lymphadenopathy(10), peritoneum(2), 
lung(2) and bone(1).The regimen was FA 45mg, 5-FU 500mg/m² 
iv bolus, Cisplatin 70mg/m², Streptozocin 1000mg/m², q21 days. 
Mean age at diagnosis was 55.7 years (range 26-77 yrs), median 
number of cycles administered  6 (range 1-12). Response was 
assessed by RECIST, and toxicity by CTC criteria. Results: 23 of 
25 patients had assessable disease.8 patients (34%) had a partial 
response, 9 (39%) stable disease, and 6 (26%) progressive disease. 
11 patients had grade3/4 toxicities: diarrhoea (3), vomiting(3), 
neutropaenia (2), neuropathy(1),fatigue(1), thrombocytopaenia (1). 
There was 1 episode of neutropaenic sepsis and no treatment 
related deaths. Median time to progression was 12 months; median 
overall survival has not been reached. Conclusions:  In this 
heterogeneous group of patients, FCiSt shows comparable response 
rates to previous regimens with acceptable toxicity. Phase III trials 
are required to further compare FCiSt with other regimens for 
NET. 
P160 
THE ROLE OF SPLENECTOMY IN LYMPHOMA – A SINGLE 
INSTITUTION EXPERIENCE. 
Simon J Crabb*, Tim M Illidge, Peter WM Johnson. 
Oncology Unit, Southampton University Hospital NHS Trust.
Background: The indications for splenectomy in lymphoma are 
poorly defined. We have therefore reviewed our practice to assess 
the possible role. 
Methods: We performed a retrospective review on all lymphoma 
patients from our institution who had splenectomy since 1990. 
   Results: Twenty nine patients were identified as shown below.
Diagnosis    n  Splenectomy Indication n
Small lymphocytic lymphoma  13 Diagnosis/sole site  9
Marginal zone lymphoma  6  Myelosuppression  8
Follicular lymphoma  4  Hypersplenism 7
Mantle cell lymphoma  2  Sole relapse site 2
Diffuse large B cell lymphoma 1  Unclear  3
Peripheral T cell lymphoma  1 
MALT lymphoma  1 
Hodgkins disease  1 
Mean age was 60 at diagnosis. Nine patients had transient peri-
operative complications (5 infective, 2 cardiovascular, 1 urinary
retention) with no deaths. Median survival is 59 months (8–178) 
from diagnosis, and 42 (6–109) post-splenectomy. 12 had 
splenectomy as primary therapy (2 with chemotherapy) with 7 
(58%) in complete remission at a mean follow up of 68 months 
(36–101). 7 had splenectomy as second line therapy with 3 free 
from progression (9, 19 and 24 months follow up) and 4 relapsed 
(at 1, 2, 21 and 42 months). 10 patients have had no therapy post-
splenectomy at mean follow up of 56 months (9–109). 5 patients 
were transfusion dependant which resolved in each post-
splenectomy. Platelet mean pre-splenectomy was 90x10
9/L (11-
217, six <50) and 424 (43–1320, one<50) one month post.
Conclusion: Splenectomy has a role in lymphoma therapy when 
the spleen represents the dominant disease site. It may be curative 
or provide durable relapse free survival, and has tolerable sequelae. 
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NON-HODGKIN’S LYMPHOMA OF THE OCULAR
ADNEXAE; THREE DECADES OF EXPERIENCE AT A
SINGLE UK CENTRE. 
Anne C Armstrong
*, John Chapman, Shankar S. Banerjee, Joan L 
Noble, Brian Leatherbarrow, W David J Ryder, Richard Bonshek, 
David P Deakin, Richard A Cowan and John A Radford.  
CRUK Dept of Medical Oncology, Depts of Histopathology and  
Clinical Oncology, Christie Hospital, Manchester UK.   
 
      Between 10/77 and 12/00, 106 pts with non-Hodgkin’s 
lymphoma (NHL) involving the ocular adnexae were subjected to 
histology review, staged and treated. Clinical data for the entire 
cohort was obtained and, where possible, biopsies were reviewed a 
second time and categorised according to the WHO classification.  
      A second histological review was possible for 55 of the 106 
cases. Confirmed histological subtypes were follicular (n=7), 
diffuse large B-cell (n=6), lymphoplasmacytic (n=5) and mantle 
cell (n=3). The remaining 34 cases were B-cell lymphomas of 
indolent type that were thought likely to be extra-nodal marginal 
zone (MZL) but could not be confirmed as such. Clinical data for 
all 106 pts were examined. The median age at presentation was 66 
yrs (range 11-92) and 58 were female and 48 male. 77 pts had stage 
IE disease, 14 stage II, 1 stage III and 14 stage IV. Treatment was 
radiotherapy (RT) alone in 81 cases, chemotherapy (CT) alone in 9 
cases and RT and CT in 12 cases. With a median follow-up for 
survivors of 6.5 yrs (range 1.3-21.4), 62 pts are alive and 44 have 
died (18 from NHL, 6 from other cancers and 20 from non-
malignant causes). Median overall survival (OS) for the whole 
group is 11 yrs (95% CI 8.1-17.8); 5yr OS for the 91 pts with 
stages I/II is 78% and 54% for the 15 pts with stages III/IV.  
   The majority of ocular adnexal lymphomas are of indolent B-cell 
type, stage IE at diagnosis and have a good prognosis following 
treatment with RT. There is a high incidence of probable MZL and 
the molecular genetics of this subgroup are being investigated. 
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THE EFFECT OF PROTEASOME INHIBITION WITH
BORTEZOMIB(VELCADE
TM) IN B CELL LYMPHOMA CELL  
LINES SJ Strauss*
1, W Liu
1, L Maharaj
1, R Shringarpure
2, C  Anderson
2, D 
Schenkein
3  TA Lister
1, SP Joel. Dept. Medical Oncology, St Bartholomew’s 
Hospital, West Smithfield, London
1; Jerome Lipper Multiple Myeloma Center,
Dept Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
2, 
Millennium Pharmaceuticals, Boston, MA, USA
3. 
   Introduction: The proteasome degrades ubiquitinated proteins involved 
in regulating cell growth, the cell cycle and apoptosis.  Bortezomib 
(Velcade
TM, formerly known as PS-341) is a proteasome inhibitor with 
cytotoxic activity in a number of malignant cell lines, and in a phase III 
trial of patients with multiple myeloma. The effect of bortezomib in 3 
lymphoma cell lines was investigated, to examine efficacy, and investigate 
factors influencing activity.  Methods and Results: The effect of 
bortezomib on proteasome activity was examined by chymotryptic 
enzyme analysis.  Proteasome inhibition was apparent at 2 hrs and 
comparable in all cell lines: DHL-4: 86 ± 3%, DHL-6: 78 ± 9%, and 
DHL-7: 84 ± 1%.  Bortezomib induced concentration-dependent growth 
inhibition and reduction of cell viability in all cell lines.  The IC50 for % 
viability after a 3-day drug exposure was: DHL-4: 26nM, DHL-6: 3nM 
and DHL-7: 7nM.  Cell cycle analysis by flow cytometry revealed a 
concentration-dependent increase in apoptosis (A) in the more sensitive 
DHL-6 and DHL-7 cells with a reduction in G1 and G2. In contrast, 
similar effective doses resulted in a G2 block in DHL-4 cells with a 
smaller increase in apoptosis (Table). 
Table: Effect of bortezomib on the cell cycle in DHL-4 and DHL-7 cells 
DHL-4                    DHL-7 
0nM 25nM 
     IC50 
100nM 
  4xIC50 
0nM 10nM 
   IC50 
30nM 
  4xIC50 
A  2 ± 1  10 ± 3  17 ± 4  5 ± 2  17 ± 4  41 ± 1 
G1  57 ± 5  52 ± 1  44 ± 1  56 ± 3  45 ± 8  30 ± 2 
S  18 ± 1  4 ± 1  8 ± 1  19 ± 1  20 ± 1  14 ± 2 
G2  21 ± 2  34 ± 1  32 ± 3  18 ± 1  13 ± 1  13 ± 1 
Conclusion: Bortezomib is effective at low nanomolar concentrations in 3 
lymphoma cell lines. Although proteasome inhibition was equivalent, 
sensitivity varied and resulted in different effects on the cell cycle. 
Possible mechanisms for this difference, including the role of p53 and 
effects on cell cycle regulatory proteins are being examined. 
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HIGH DOSE INTERFERON-α-2b ADJUVANT TREATMENT
FOR MELANOMA: THE UK EXPERIENCE
*Effie Katerinaki, Bihani Kularatne, Rachel Hambly, Lesley
Turner, Barry W. Hancock and Paul Lorigan on behalf of the UK
collaborators
Academic Department of Clinical Oncology, Weston Park Hospital,
Sheffield, S10 2SJ, UK
      The objective of this study was to review the toxicity and 
feasibility of high dose Interferon-α-2b adjuvant treatment for 
melanoma patients reported to a national database from 18 UK 
centres. 
      One hundred and twenty three patients (median age 47 years) 
were reported for the one month i.v. induction phase.  Fever, 
fatigue, leucopenia and hepatotoxicity were the commonest 
toxicities. Dose delays were required for 33% and dose reductions 
for 45% of the patients at least once and the commonest causes 
were neutropenia and hepatotoxicity. The majority of the patients 
(90%) completed the 4-week regimen.  
Sixty nine patients (median age 42 years) were reported for the 
eleven month maintenance phase. No data for dose modifications 
were available. Grade I and II constitutional symptoms, leucopenia 
and hepatotoxicity were mostly reported and the incidence declined 
during the course of treatment. 68% of the patients who entered this 
phase completed treatment on protocol until one year or disease 
progression/death.  
In conclusion, high dose Interferon-α-2b treatment was feasible 
but the associated toxicity was significant and similar to that 
previously reported by the ECOG studies. This regimen is the 
standard of care for stage IIB/III melanoma in USA and is gaining 
acceptance in UK. Close treatment monitoring is essential, and the 
toxicity must be carefully balanced against benefit to patients.
P164 
TNF-α INCREASES HUMAN MELANOMA CELL INVASION
AND MIGRATION in vitro -THE ROLE OF PROTEOLYTIC
ENZYMES
*Effie Katerinaki, Gareth Evans, Paul Lorigan and Sheila MacNeil.
Academic Department of Clinical Oncology, Weston Park Hospital,
Sheffield, S10 2SJ.
  Background: We have previously shown that the proinflammatory
cytokine TNF-α upregulates human melanoma cell attachment to
ECM substrates, invasion through fibronectin and integrin subunit
expression (Zhu et al, J Invest Dermatol 2002; 119: 1165-1171). 
Aim: The aim of this study was to examine whether the effects of
TNF-α on melanoma cell invasion and migration in vitro are
mediated by upregulation of, or activation of degradative enzymes.  
Materials and methods: We used human recombinant TNF-α to
study its effect on the invasion of the human cutaneous melanoma 
cell line HBL through fibronectin over 20 hours, cell migration over 
24 hours (“scratch wound” assay), expression/activation of MMPs-2
and MMP-9 (detected by gelatin zymography) and general protease 
activity (detected by quenched fluorescent substrate assay)
measured at 24 hours. We also used the general protease inhibitor 
α2 macroglobulin to study its effect on HBL cell invasion and
migration. 
Results: TNF-α significantly increased melanoma cell invasion 
through fibronectin by +35% and cell migration on plastic by +21% 
above control (non-treated cells). The cells expressed low levels of
latent MMP-2 (and no MMP-9) and general proteolytic enzymes 
that were not activated or upregulated by TNF-α. However, the
TNF-α stimulated invasion through fibronectin and migration were
inhibited by α2 macroglobulin. 
Conclusions: TNF-α significantly increases melanoma cell
invasion and migration in vitro. This effect may be partially
mediated by upregulation of localised peri-cellular proteolytic
enzyme activity not readily detected in general biochemical assays. 
THE EFFECT OF RECOMBINANT ERYTHROPOEITIN ON
RENAL CANCER CELL LINES AND ITS ROLE IN
CHEMOSENSITIVITY. 
Thomas Powles, Wai Liu, Jonathan Shamash, Tim Oliver and
Simon Joel. New Drug Study Group, St Bartholomew’s Hospital,
London, UK. 
Recombinant erythropoetin (rEpo) has an important role in the
management of cancer patients. However, the effects at a cellular
level are still poorly understood. We examined the effect of rEpo
alone, and in combination with cytotoxic chemotherapy, in seven
cell lines, including 3 renal lines. In particular, we assessed the
relationship between rEpo receptor expression and activation of
biochemical pathways regulating cell kill; specifically Bcl 2,
which can be up regulated by other growth factors resulting in
chemoresistance. Our results showed that rEpo did not
significantly alter cell viability, cell cycle dynamics or the rate of
cell proliferation. Flow cytometric analyses showed differences in
the level of receptor expression (range: 3.4 ± 0.7 to 39.5 ± 2.2),
with the renal cell lines having the highest rEpo receptor level
(>17.5 ± 5.5). As there were no changes in the cell parameters, we
investigated the activation of Erk by means of immunoblot
analyses. Phosphorylated Erk was up regulated following culture
with rEpo in the cell lines expressing a high level of the receptor.
However there was no subsequent up regulation of Bcl-2 protein
levels. The culture of cells pre-treated with rEpo with cytotoxic
EC50 concentrations of cisplatin did not result in an altered
magnitude of % cell kill. These results highlight the complexity of
the rEpo-signalling pathway, and suggest that unlike other growth
factors, Bcl-2 is not up regulated following its use. Therefore, the
use of rEpo appears to be safe in this setting, even in renal
tumours that express higher levels of the receptor.
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ESSENTIAL REQUIREMENT OF APOLIPOPROTEIN J
(CLUSTERIN) SIGNALLING FOR IKB EXPRESSION AND
MODULATION OF NF-KB ACTIVITY: IMPLICATIONS FOR
NEUROBLASTOMA   Giorgia Santilli, Bruce J. Aronow and Arturo
Sala* 
Molecular Haematology and Cancer Biology Unit, Institute of Child
Health, UCL, London WC1N 1EH, United Kingdom. 
a.sala@ich.ucl.ac.uk
ApolipoproteinJ/clusterin is an enigmatic protein induced in
inflammation, apoptosis and cancer. In spite of extensive studies, its
biological function has remained controversial. We have recently
observed that Apolipoprotein J is directly regulated in neuroblastoma
cells by B-MYB, a protooncogenic transcription factor involved in cell
proliferation and survival. Here we show that Apolipoprotein J can
modulate survival and in vitro and in vivo invasive potential of
neuroblastoma cells. Since it has been reported that these biological
properties can be regulated by NF-kB, we explored the possibility that
Apolipoprotein J might interfere with NF-kB signalling.  
  Remarkably, exogenous Apolipoprotein J expression strongly inhibited
NF-kB activity in human neuroblastoma cells and murine embyonic
fibroblasts by stabilising inhibitors of NF-kB (IKBs). Steady state levels
of IKB proteins are drastically reduced in mouse embryo fibroblasts after
disruption of the Apolipoprotein J gene. Absence of ApoJ caused reduced
IKB expression, a TNF-dependent increase in NF-kB activity, and
increased transcription of the NF-kB target gene c-IAP.  
These results suggest that an unexpected physiological role of
Apolipoprotein J is to suppress NF-kB signalling through stabilisation of
IKBs.  
P168 
EFFECTS OF KETOCONAZOLE AND ACITRETIN ON 
RETINOID ISOMERISATION AND METABOLISM IN 
NEUROBLASTOMA 
Jane L. Armstrong*, Gareth J. Veal, Christopher P. F. Redfern and
Alan V. Boddy. Northern Institute for Cancer Research, University
of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH. 
   Treatment with 13-cis retinoic acid (13cisRA) has been shown to
significantly improve clinical outcome in high-risk neuroblastoma
(nbl). Isomerisation to all-trans retinoic acid (ATRA) potentiates
the cellular activity and growth inhibitory effects of 13cisRA in
nbl cells in vitro. The major route of RA catabolism is thought to
be oxidation mediated by specific P450 enzymes. Cellular retinoic
acid binding proteins (CRABPs) are also thought to regulate free
intracellular ATRA levels by promoting metabolism. We have
evaluated the effect of acitretin, an analogue of RA known to bind
strongly to CRABPs, and the P450 inhibitor ketoconazole, on
13cisRA isomerisation and metabolism in nbl cells in vitro. 
   SHSY5Y cells were incubated with either acitretin (100 µM) or
ketoconazole (20 µM) for 24h prior to incubation with 13cisRA
(10  µM) for a further 24 h. Cell pellets were collected and
intracellular retinoids extracted prior to analysis by HPLC.
CRABP expression was assessed by western blot analysis. 
Pre-incubation with acitretin resulted in a selective increase in
intracellular ATRA concentrations (26-fold). The extent of this
increase correlated with induction of CRABP in the cells studied.
Pre-incubation with ketoconazole lead to an increase in both
intracellular ATRA (5-fold) and 13cisRA (2.5-fold) levels
suggesting an inhibition of metabolism of both isoforms. 
These data indicate that the extent of 13cisRA isomerisation and
metabolism in nbl cells can be modulated by acitretin and
ketoconazole.
P169 
DIFFERENTIAL SIGNALING VIA SURFACE IgM IS 
ASSOCIATED WITH VH GENE MUTATION STATUS AND
CD38 EXPRESSION IN CHRONIC LYMPHOCYTIC 
LEUKEMIA (CLL). 
Stuart Lanham*, Terry Hamblin, David Oscier, Rachel 
Ibbotson, Freda Stevenson, and Graham Packham.
Somers Cancer Research Building, Southampton General 
Hospital, Tremona Road, Southampton, SO16 6YD, UK 
  Although VH gene mutation status and CD38 expression are 
important prognostic factors for CLL, the biological differences 
which determine variable disease course have not been identified. By 
measuring increases in Syk and global tyrosine phosphorylation in 
cells treated with anti-IgM, we show that the ability to signal through 
the B-cell receptor significantly correlates with VH gene status 
(p=0.003) and CD38 expression level (p=0.00009). Overall, 71% of 
unmutated cases (n=21) responded compared to 30% of mutated 
cases. Failure to signal through ligation of IgM could be 
circumvented by ligation of IgD (19/29 samples tested) or the BCR-
associated molecule CD79a (23/29 samples tested). Retention of 
responsiveness to IgM-ligation may contribute to the poor prognosis 
of the unmutated and CD38 positive subsets. Our results also suggest 
that multiple mechanisms underlie non-responsiveness to IgM-
ligation in CLL. The pattern of differential signaling indicates 
possible differences in the molecular organization of the BCR, and 
points to features of anergy in the mutated subset.
   The prognostic power of the in vitro response to IgM ligation 
remains to be determined in a large series, but the simple technology 
involved may present an alternative/additional test to VH gene 
analysis for predicting clinical course. 
P170 
DEVELOPMENT OF A TOUCH SCREEN QUESTIONNAIRE 
APPROACH FOR MEASUREMENT OF PAIN ASSESSMENT 
SCALES IN CANCER PATIENTS WITH BONE METASTASIS 
Iain M Goodhart, Janet E Brown*, Susan Ellis, Sandra Gutcher, O 
Prakash Purohit, Robert E Coleman, Academic Unit of Clinical
Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, 
UK. 
Pain is one of the most common features in patients with cancer and has a 
significant impact on quality of life, but it is often poorly assessed. For patients 
with metastatic bone disease of the breast and prostate, survival is often 
measured in years rather than months and the assessment of bone pain and its 
reduction are major clinical goals.The success of treatment in such patients is 
often assessed by measuring the change in objective pain scores, which take the 
form of paper questionnaires and pain scales, which can be time consuming to 
complete and score correctly. We report a pilot study to develop and evaluate a 
patient-operated, computerised, touch-screen, pain questionnaire which was 
aimed at improving the efficiency of data entry and the quality of the 
patient/questionnaire interface. 
 Touch screen questionnaires for this application were not commercially 
available and the script enabling the questionnaire to operate was specifically 
written for the study. Pain scores from the touch screen approach were 
compared with those from two existing paper format pain questionnaires, the 
Wisconsin Brief Pain Inventory and a locally developed pain scale. With Ethical 
Committee approval each patient had all three pain scores measured at four 
separate visits.
  Statistical analyses of the data were conducted on completed data sets from 29 
patients with bone metastases from breast or prostate cancer. 86% of patients 
were happy to use the touch screen format, with only 14% of patients preferring 
the paper questionnaires. Moreover, the touch screen version could be 
completed in around half the time of the paper version, with fewer unanswered 
questions.  In addition, the touch screen version automatically computed the 
pain scores. It was shown that touch-screen and paper linear analogue scales 
were comparable with a mean score difference of 5.5% and Pearson product 
moment correlation coefficients in the order of 0.9. It is envisaged that this work 
will lead to the further development of refined touch-screen questionnaires for 
assessment of pain scores. 
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LEVOMEPROMAZINE VERSUS DEXAMETHASONE WITH
METOCLOPRAMIDE IN THE PREVENTION OF CISPLATIN
INDUCED DELAYED EMESIS. PRELIMINARY RESULTS OF
A RANDOMIZED STUDY.
Joseph Sgouros*, Helen Neville-Webb, Suzan Bunton, Mike J.
Lind, Anthony Maraveyas, Academic Department of Oncology,
Princess Royal Hospital, Hull, UK
We have previously reported that Levomepromazine is a useful
agent for chemotherapy induced delayed vomiting salvage. The
primary endpoint of this study is to compare Levomepromazine
(Nozinan) at its oral novel formulation of 12.5mg bd for 3 days
(Arm A) with the standard combination of Dexamethasone 8mg bd
for 2 days followed by 4mg bd for 2 more days and
Metoclopramide 10mg tds for 5 days (Arm B) in the prevention of
ECF/ MCF induced delayed nausea and vomiting. Eligible patients
have gastric/oesophageal carcinoma with no GI compromise and
no pre-treatment vomiting. Study antiemetics are commenced 16
hours post Cisplatin. NCI common toxicity criteria are used and
patients with ≥grade 2 N&V are being crossed over to the
alternative arm Since no phase II data existed, an early analysis
when 40 patients had been recruited was deemed necessary. So far
15 patients (80% men, mean age 59, median PS 80%) have been
allocated in Arm A and 17 (94% men, mean age 66, median PS
80%) in Arm B. Complete control of delayed nausea and vomiting
in the 1
st cycle of chemotherapy was achieved in 54% and 69% of
patients in Arm A and 26% and 40% in arm B respectively (NS).
In subsequent cycles the complete control of nausea and vomiting
in both arms was almost the same. 30% of patients in Arm A and
20% in Arm B needed to be crossed over after the 1
st cycle. More
patients in Arm B had insomnia (10% vs 47%) (p<0.005).
Recruitment of patients continues.     
P172 
PROTEOLYTIC DIGESTION OF A TUMOUR-DERIVED
LIPID MOBILISING FACTOR AND SUBSEQUENT
IDENTIFICATION OF AN ACTIVE FRAGMENT.
Paul M SANDERS*  and Michael J TISDALE; Pharmaceutical
Sciences Research Institute, Aston University, Birmingham, UK
B4 7ET 
Cancer cachexia comprises unintentional and debilitating weight
loss that accompanies specific tumour types.  Cachexia reduces
efficacy of chemotherapy, prognosis and patient quality of life. 
Adipose depletion in cachexia is mediated by a 43KDa
glycoprotein Lipid Mobilising Factor (LMF).  LMF appears
homologous to the endogenous peptide Zinc Alpha-2 Glycoprotein
(ZAG). 
      To unlock the therapeutic potential of this molecule and to
enable adequate receptor-interaction studies, it was investigated
whether the molecule could be fragmented whilst retaining
lipolytic activity. 
LMF was purified from the urine of pancreatic cancer patients
and loaded onto an immobilised trypsin HPLC column.  The eluate
was subjected to sephadex G50 size exclusion chromatography.
Resulting fractions were assayed for lipolytic activity by
monitoring glycerol release from isolated murine epidydimal white
adipose tissue.
A low molecular weight fraction was produced which retained
lipolytic activity.  Active fragment size was estimated at
approximately 6-12 KDa following G50 column standardisation
and fraction electrophoresis against ultra low molecular weight
markers.  A digestion of ZAG in this manner also yielded a similar
active fragment, providing evidence for homology between LMF
and ZAG.
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THE VICTOR TRIAL (VIOXX® IN COLORECTAL CANCER
THERAPY, DEFINITION OF OPTIMALREGIME) 
*Stuart Pendlebury, Francesca Duchesne, Katharine A Reed, 
Justine L Smith, David J Kerr (On behalf of the VICTOR Trial
Advisory Group) 
Epidemiological, clinical, animal and laboratory studies have
demonstrated that non-steroidal anti-inflammatory drugs (NSAIDs)
may prevent colorectal carcinogenesis. However the use of
traditional NSAIDs, which inhibit both forms of cyclo-oxygenase
(COX-1 and COX-2) has been restricted because of their
gastrointestinal toxicity. The recently developed COX-2 selective
NSAIDs exhibit a reduced incidence of gastrointestinal side effects
when compared to traditional NSAIDs whilst retaining their anti-
neoplastic properties, raising the possibility that they may be
effective not only for chemoprevention but also as adjuvants to
existing therapies or for the development of novel therapies for
colorectal cancer.   
The VICTOR study is a phase III, randomised double blind,
placebo-controlled trial of the COX-2 selective inhibitor rofecoxib
(VIOXX
®) in colorectal cancer patients following potentially
curative therapy. The VICTOR trial compares rofecoxib to placebo
with the expectation that patients will experience increased overall
survival and relapse free survival on taking rofecoxib for at least
two years. The difference in the survival outcomes between two
and five years of treatment is also under investigation. The study is
an international trial, recruiting 7000 patients over 5 years. UK
centres began recruitment in April of 2002. Centres in North
America and Australasia will begin randomisation of patients in
2003. Study completion and final analysis is expected in 2012.
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ACTIVATION OF PKC AND NFkB BY A
PROTEOLYSIS INDUCING FACTOR (PIF)
IN CANCER CACHEXIA. 
*StaceyM. Wyke, Helen J. Smith and Micheal
J. Tisdale.Aston University, Aston triangle,
Birmingham, B4 7ET. 
  Proteolysis Inducing Factor (PIF) is a 24kDa glycoprotein that can 
be isolated from cachexia-inducing murine and human tumours and 
from the urine of cachectic cancer patients. PIF causes breakdown of 
skeletal muscle, both in vivo and in vitro through the activation of the 
ubiquitin – dependant proteolytic pathway. The mechanism by which 
this occurs was studied in C2C12 myotubes as a surrogate model for 
skeletal muscle. PIF increased 26S proteasome activity (represented by 
‘chymotrypsin like’ activity in C2C12 myotubes at concentrations 
between 1 – 20nM and maximum stimulation was achieved at 4.2nM 
(p=<0.001). This effect was attenuated by the PKC inhibitors Ro31-
8220 and calphostin C.
The PKC inhibitor calphostin C demonstrated inhibition of IkBa 
degredation in response to PIF, inhibiting translocation of NFkB to the 
nucleus. Calphostin C also inhibited translocation of PKC in response 
to PIF. The action of PIF was also attenuated by the NFkB inhibitor 
curcumin, with regard to chymotrypsin like activity, 20S and E2 
expression, suggesting that NFkB may be involved in the regulation of 
the ubiquitin – dependant proteolytic pathway.
 These results suggest that the PKC and NFkB pathways are exploited 
by PIF in cancer cachexia.  
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MOLECULAR ANALYSIS OF THE PDG
PATHWAY IN CHILDHOOD MEDULLOBLAS
Jacqueline A. Langdon*, Roberto Hernan, Jennifer Atkinson,
Richard J. Gilbertson and Steven C. Clifford
Northern Institute for Cancer Research, Unive
Newcastle-upon-Tyne, U.K. & St Jude Children’s Re
Hospital, Memphis, TN, U.S.A.
Medulloblastoma (MB) is the most com
tumour of childhood. Current survival rates are 50-60% and cl
predictors of poor outcome include age (<3y
metastases.  Molecular mechanisms underly
may provide more informative insights into t
clinical behaviour; however, the molecular basi
poorly understood. 
A recent microarray gene expression profile 
reported up-regulation of platelet-derived 
(PDGFR-α) and the downstream RAS/MAP
pathway to be associated with advanced m
[MacDonald et al. (2001) Nat Genet. 29: 143
genetic activation of this pathway in a panel of 28 prim
9 MB cell lines by mutational analysis of H
RAF. No activating mutations were found in any
Western blot analysis identified moderate-high l
protein in 3/28 MB tumours; however, this
metastatic disease or any other clinical feature. 
that activation of the PDGFR-α/RAS/M
infrequent event in MB. We are currently analy
levels and PDGFR-α mutational status in the
tumours to determine whether pathway acti
alternative mechanisms. 
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THE ICR CLINICAL TRIALS & STATISTICS UNIT – AN
OVERVIEW OF PRESENT WORK & FUTURE PLANS Lindsay
Johnson*, Judith M Bliss, Emma Hall ICR-CTSU, Brookes
Lawley Building, Institute of Cancer Research, Sutton SM2 5NG
  During 2002, 2671 patients were randomised into Phase III multicentre 
trials conducted by the Clinical Trials & Statistics Unit at the Institute of 
Cancer Research (ICR-CTSU).  Six multicentre trials are currently open 
to recruitment (TACT, HRT Trial, HERA, BC2001, Intercontinental, 
and the SLNB Melanoma Trial). 12434 patients are in active follow-up 
in multicentre trials now closed to recruitment (START, ABC, Topic I & 
II, Trafic, AHT, MSG-BAPS, Breast Dosimetry and Breast 
Fractionation.  7 multicentre trials are under development.  Trials in 7 
disease sites are conducted with breast as the specialist area of research 
activity.
  The ICR-CSTU embraces the spirit of national collaboration by 
developing trials in conjunction with principal investigators and trials 
groups based throughout the UK.  This is furthered by ensuring the 
involvement of the NCRI clinical studies groups. 
  A successful track record in building banks of biological material has 
been established, with large national collections of paraffin embedded 
material (ABC, TACT), and blood samples (START, TACT).  Through 
this activity we have ongoing collaborations with established UK experts 
in translational research. 
  Our Phase III multicentre trials incorporate Quality of Life(QOL) 
studies, which form an integral component and are run from ICR-CTSU. 
QOL studies are developed in collaboration withnationally recognised 
QOL experts. 
  In keeping with our philosophy of national collaboration, we actively 
seek input from a broad base of UK clinicians and other UK trials groups 
in developing and running our trials.  Effective mechanisms through 
which to acknowledge the contribution made by regional research 
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AN EVOLVING MODEL FOR FLEXIBLE TRIAL CO-
ORDINATION – THE AZURE TRIAL
Liz Graham*, Vicky Napp, Stephanie Pollard
Northern & Yorkshire Clinical Trials & Research Unit,
University of Leeds, 17 Springfield Mount, Leeds, LS2 9NG
The AZURE Trial is a new international multi-centre randomised 
controlled phase III trial which aims to assess the benefits of adding 
adjuvant Zoledronic acid (bisphosphonate) to standard treatment for 
women with high risk localised breast cancer.  3300 patients are to be 
recruited over a maximum period of 3 years in order to answer this 
important question within a reasonable time frame.
The most effective way to achieve optimum recruitment rates was seen 
to be the implementation of the “hub and spoke” organisational model. 
This has been successful in a number of other large breast cancer trials.  
In the case of AZURE, the Northern & Yorkshire Clinical Trials & 
Research Unit are acting as co-ordinating centre (“hub”), working 
alongside other UK and international trials units (“spokes”) who will 
take responsibility for local investigators and data management.
A similar model exists within the Yorkshire Breast Cancer Research 
Group, the “hub” in this case being the YBCRG, with “spokes” 
including research working groups, regional trusts, NCRN, NYCTRU, 
BIG and the EORTC.   These links remain and will be integrated into 
the AZURE hub and spoke structure. 
The NYCTRU intend to work flexibly with the aim of making 
recommendations as to the most effective organisational procedures.  
Anticipated benefits include strengthening of links within and between 
NHS trusts, cancer research networks/groups, and trials units across the 
country, with resulting improvement in communication, collaboration 
and recruitment. 
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ESTABLISHMENT OF A DNA RESOURCE THROUGH THE
GELCAPS CONSORTIUM TO STUDY LOW PENETRANCE
SUSCEPTIBILITY ALLELES FOR LUNG CANCER
A. Matakidou*, T. Eisen, M. O’Brien, R.S. Houlston and members
of the GELCAPS Consortium. Sections of Medicine & Cancer
Genetics, Institute of Cancer Research, Sutton, Surrey, SM2 5NG    
There is increasing evidence for the existence of inherited 
susceptibility to lung cancer. It is likely that at least part of this is 
mediated by the action of low-penetrance alleles. Identification of 
genes in this class is contingent on association studies. To detect 
these alleles which confer small genotypic risks of around 1.5  
requires large cohorts of cases and controls. Most studies reported 
to date have been under-powered and perhaps not surprisingly have 
produced discordant findings. To undertake a large-scale study of 
this nature, we have established the GELCAPS (GEnetic Lung 
CAncer Predisposition Study) Consortium to ascertain and collect 
blood samples and lifestyle information of 2,000 patients diagnosed 
with lung cancer in the UK. Coupled with this we are collecting a 
similar number of controls. To date we have collected 1,300 cases.  
Through this we shall have access to a systematic series of 2,000 
unselected lung cancer cases and controls. Initially we are using this 
resource to evaluate the role of common variants within DNA repair 
enzymes and determinants of methylation status (MTHFR) using 
known and newly identified SNPs. Genotyping is being undertaken 
using TAQ man technology and preliminary results on the first 
1,000 cases and controls will be analysed by August 2003 and 
presented at the meeting. Once technology permits, we shall use our 
resource for a genome-wide screen to identify novel low-penetrance 
lung cancer genes. 
 
GELCAPS has been sponsored by Aventis and Dr Matakidou is 
supported by the Alan J Lerner Research Fund at the Royal 
Marsden Hospital. 
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CANCER DIVISION, MRC CLINICAL TRIALSUNIT:
SUMMARYOF TRIALS.  Simon Weedon, Cancer Division,
MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA
(tel: 0207670 4700;fax: 020 7670 4818; email:
contact@ctu.mrc.ac.uk;http://www.ctu.mrc.ac.uk). 
The Cancer Division of the Medical Research Council Clinical
Trials Unit designs, conducts and analyses many large randomised
clinical trials covering most tumour sites. 
Four trials will be presented in the Clinical Trials Showcase at
this year’s meeting: BO06, a randomised trial of chemotherapy
with or without granulocyte colony-stimulating factor in operable
osteosarcoma; ICON4, a randomised trial of paclitaxel in
combination with platinum vs conventional platinum-based
treatment in relapsed ovarian cancer; LU21, ifosfamide,
carboplatin and etoposide with mid-cycle vincristine versus
standard practice chemotherapy in patients with small cell lung
cancer; and ST02 (MAGIC), a randomised controlled trial or pre-
and post-operative chemotherapy in patients with operable gastric
and lower oesophageal cancer.  
We have recently opened three new trials: OE05, comparing
chemotherapy regimens in patients with resectable
adenocarcinoma of the oesophagus; BR12, temozolomide vs PCV
chemotherapy in the treatment of recurrent malignant glioma; and
MS01, active symptom control with or without chemotherapy in
the treatment of patients with malignant pleural mesothelioma. 
Two trials have recently closed: TIP, a study of paclitaxel,
cisplatin and ifosfamide for metastatic germ cell tumour which has
relapsed following BEP chemotherapy; and BS06, radical
radiotherapy in the management of pT1G3 TCC in superficial
bladder (BS06). 
We have an extensive portfolio of open trials covering all major
disease sites, these are listed on our poster. 
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META-ANALYSIS GROUP, MRC CLINICAL TRIALS UNIT:
SUMMARY OF RESEARCH.Clair vale, Meta-analysis Group,
MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA
(tel: 020 7670 4700; fax: 020 7670 4816; email:
metaanalysis@ctu.mrc.ac.uk; http://www.ctu.mrc.ac.uk). 
The Meta-analysis Group of the Medical Research Council
Clinical Trials Unit designs and conducts systematic reviews and
individual patient data (IPD) meta-analyses in a variety of
diseases, notably cancer.  We work closely with the Cochrane
Collaboration, both in the conduct of systematic reviews and meta-
analyses and also in methodological research.  The Group also
coordinates a national register of randomised cancer trials,
(formerly the UKCCCR Register) and is involved in a number of
initiatives in trial registration. 
The results of one IPD meta-analysis will be presented at
this year’s meeting, in the Current Controversies in
Gynaecological Cancer Symposium: “Is neoadjuvant
chemotherapy of benefit in the treatment of locally advanced
cervical cancer?”
Highlights of other projects will be detailed in this poster,
including: results of a recently completed IPD meta-analysis of
neoadjuvant chemotherapy in invasive bladder cancer, progress
reports on ongoing and forthcoming IPD meta-analyses and
summaries of our portfolio of methodological research.  
The poster will also outline developments in trial
registration, drawing attention to recent improvements to the
cancer trials register and its website, featuring the new-look site
with enhanced facilities for trial registration. 
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DOCUMENTATION ASSOCIATED WITH USE OF IV
PALLIATIVE CHEMOTHERAPY (PC) - AN EXAMPLE OF
THE USE OF THE AUDIT PROCESS TO CHANGE
CLINICIAN BEHAVIOUR. * Jean.Abraham, Astrid.Mayer,
Gemma.Whiting, Helena.Earl, Margaret.Moody. Oncology Dept
Addenbrookes NHS Trust, Cambridge CB2 2QQ. 
  Aims: An initial audit was performed in 1999 to ascertain if IV 
PC was given according to departmental guidelines and to assess 
adequacy of associated documentation. The results required in 
documentation. Use of toxicity flow sheets was recommended.  
The current audit was used to assess whether the changes 
implemented had achieved improved documentation. 
 Method: 75 randomly selected notes of non-trial patients (upto 
10 per consultant) who received IV PC between 05/01 to 05/02 
were audited. Documentation data, collected by means of a pro 
forma, included: Performance Status (PS) (each cycle); treatment 
toxicity (TT) (each cycle); symptoms documented (before 
present cycle); reasons for giving chemotherapy; evaluable 
disease; number of cycles planned; interim response assessment 
(planned or completed); location of primary; current regimen. 
 Results: A comparison of current (CA) and previous (PA) audit 
results showed documentation of; PS 77% (CA) 23% (PA); TT 
96% (CA) 62% (PA); Symptoms 98% (CA) 83% (PA);reason for 
giving chemotherapy 92% (CA) 89% (PA); evaluable disease 
95% (CA) 96% (PA). 
 Conclusion: There was a marked improvement of 
documentation overall. The implementation of toxicity 
flowcharts as recommended by the 1999 initial audit significantly 
improved the level of adequacy of documentation where used. 
P182
EXPECTATIONS COMPARED TO ACTUAL QUALITY OF LIFE 
IN PATIENTS WITH HEAD AND NECK CANCER Roger. 
Wheelwright*, Martin A. Birchall University of Bristol, Medical 
School Unit, Southmead Hospital, Bristol BS10 5NB, England, UK  
Background   Past outcome measures have mainly to date been based on 5 
year survival now increasing attention is being paid to quality of life (QoL) 
as an outcome tool. Overview   As part of a Critical Path Analysis study 
one objective was to address the question: Does patient QoL at four months 
and one-year match their expectations at pre-treatment stage? 
Conclusions   A high level of anxiety and depression with low expectations 
was anticipated with this group of patients, the results indicate otherwise. 
Although interesting, definitive conclusion cannot be made for the quality 
of life findings, a further study of quality of life needs to be done with a 
larger cohort of patients. 
Expectations and Actuality: 4  months/1yr Questionnaire: 4/12 months 
ago, before your treatment, what did you expect your physical condition 
to be now? and 4/12 months ago, what effect did you think the treatment 
will have on your overall Quality of Life?  
Results   Analysis of the patient scores demonstrated low scores for 
anxiety and depression, with no indication of clinical depression amongst 
the subject group.
Limitations of findings: Sample size small n=21, Results from one centre
Subjects   Patients for this study were those presenting for the first time 
with head and neck cancer to the centres during a 12-month study period.
Quality of Life tools: EORTC with Head and Neck Module, Hospital 
Anxiety and Depression Scale  (HADS), two expectations and actuality 
questions added, questionnaire given at 1st OPA, 4 months and 12 months
Expectations and Actuality: 1st Questionnaire: What do you expect your 
overall physical condition will be in 12 months, after your treatment? and 
What effect do you think the treatment will have on your overall Quality of 
Life in 12 months time?  
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A STUDY TO EVALUATE THE USE OF CA125 IN OVARIAN
CANCER (EOC) FOLLOW-UP (FU).  A CHANGE IN
PRACTICE LED BY PATIENT PREFERENCE Jennie Pratt, 
Cheryl Palmer, Bristi Basu, Jean Abraham, Swethajit Biswas, 
James Brenton, Helena Earl*.  Dept. of Oncology, Addenbrookes 
Hospital Cambridge CB2 2QQ 
Introduction: Pre-study, women on FU for EOC had blood taken
for Ca125 at their clinic visit (Ca125-FU).  Symptomatic patients 
were informed of the result by phone, asymptomatic patients with 
elevated or normal Ca125, might be informed at their next FU. 
Patients and Methods: Patient questionnaires (Q) were developed
including questions exploring their understanding of Ca125, 
satisfaction with current service, and whether they would prefer to 
have an up to date Ca125 measurement available in clinic.  A
change in practice was then implemented, and a repeat Q was sent 
to survivors two years later to assess their satisfaction with this. 
Results: Qs were sent to 100 women with EOC attending the 
centre for follow-up and 88% replied.  Only 50% of women were 
satisfied with Ca125-FU.  81% documented that they would prefer 
the current result to be available in the clinic.  A change in practice 
was instituted.  Local GPs were contacted and 100% agreed to 
carry out Ca125, 2 weeks prior to FU, using a pre-prepared pack
provided by the centre.  Women were informed of their result at 
their next clinic visit.  Two years later, a repeat Q was sent to the 
37 survivors.  92% reported improved quality of follow-up by the 
change in practice.  92% reported their results were available in 
clinic (88%  ‘always’, and 4% ‘usually’).  The repeat Q also 
reported that 88% of women had an understanding of Ca125-FU
compared with 81% from the initial study.  Conclusions: There 
was a marked improvement in patients’ perceptions of the quality
of Ca125-FU as a result of a successful change in practice led by
patients’ preference. 
P184 
CANCER CHEMOTHERAPY SERVICES IN GRAMPIAN,
ORKNEY AND SHETLAND: GOOD, BAD AND UGLY.  
Marianne Nicolson*, Susan Healy, Lynn Adams, Tanya 
Learmonth and Elaine Neil, Aberdeen Royal Infirmary, AB25 
2ZN. 
 Introduction: Throughout the NHS there is a drive to improve 
standards for treatment delivery through development of evidence-
based protocols.  The safe prescription and administration of 
chemotherapy is one area where there is a need for specialisation and 
close collaboration with all concerned practitioners. Primary and 
secondary care physicians, community and hospital nurses, 
pharmacists and other staff must all be fully aware of the safety issues 
concerned and their role in maintaining good standards of care. On 
behalf of the Grampian Medicines Committee Oncology Subgroup, an 
audit of local cancer chemotherapy services was carried out between 
25th March and 18th May 2002. 
 Method: The audit tool was the document produced by the Scottish 
Cancer Care Pharmacy Group (SCCPG).  This assesses standards set 
out by the document ‘Safe use of cytotoxics in the clinical 
environment’ recommended by the Scottish Executive (HDL 2001.13).  
There was also a spot review of casenotes in the areas visited. Two 
members of the audit team visited each of the twelve areas where 
chemotherapy is administered. Tight working definitions of the 
specific standards set by the SCCPG document were agreed. Factors 
addressed, relating to cytotoxic chemotherapy, were prescribing 
(prescriptions and protocols), preparation and supply, administration, 
disposal and  minimising exposure.  Each subsection of these headings 
was allocated a Grade of 1 where there was full compliance with the 
standard, 2 for minor non-compliance, 3 for non-compliance and 4 if 
non-compliance was major or critical.
 Results: Overall Grade 1 was achieved in less than 50% for all but the 
disposal standard.  Details and progress will be presented. 
P185 
INCREASE FROM LOW TO MODERATE DOSE-RATE IN
GYNAECOLOGICAL BRACHYTHERAPY AND DOSE
CORRECTION- A RETROSPECTIVE ANALYSIS OF
PATIENTS TREATED AT WESTON PARK HOSPITAL.
Jayaram Mohanamurali*, David J. Radstone, Simon D. Pledge, 
Weston Park Hospital, Witham Road, Sheffield, S10 2SJ. 
Although there is a general consensus amongst radiotherapists 
that a dose reduction is needed to compensate for an increased 
dose-rate in brachytherapy, the magnitude of the dose reduction 
required still remains a subject of considerable debate. 
  Clinical trials which have compared various schedules suggest an 
optimum dose reduction to be about 10-12%, for a change from
low to moderate dose-rate. 
At Weston Park Hospital, conservatively, the total dose to point-
A was reduced by 20% in patients treated with the selectron 
remote afterloading technique, compared to those treated pre-
selectron, to compensate for the increase in dose-rate in 1994.
245 case notes of patients with carcinoma of the cervix, 
registered with Weston Park Hospital in 1992, 1993, 1995 and 
1996 were reviewed. A total of 35 patients treated with two 
insertions of brachytherapy followed by external beam boost to the 
parametria were identified and included in the analysis. 20 patients
were treated pre-selectron and 15 patients were treated using 
selectron with the above regime. 
The mean point-A dose-rate in the pre-selectron group was 87.55 
cGy/hr and 135.47 cGy/hr in the selectron group. The ratio of the 
change in dose-rate was 1.55. There was no statistically significant 
difference between the two groups of patients, with regards to local 
recurrence rates or morbidity.
   Despite only a  modest  increase  in  dose-rate  at  point-A,  the 
reduction in the total dose prescribed at point-A by 20% to 
compensate for the increase in dose-rate does not appear to have an 
adverse impact on local control in this small group of patients.  
P186 
CHARACTERISTICS OF ENDOMETRIOID AND CLEAR CELL 
EPITHELIAL OVARIAN CANCER: AN ANALYSIS OF 
PROSPECTIVELY COLLECTED DATA 1984-2001Dawn J.Storey*, 
Moira Stewart, Tyzvia Rye, Awatif Al-Nafussi, Alistair R Williams, 
John F.Smyth, Hani Gabra. Cancer Research UK, University of 
Edinburgh Cancer Research Centre, Crewe Road South, Edinburgh, 
UK.
    Background:There is little published data on endometrioid ovarian 
tumour response rates to platinumbased chemotherapy (PBC).Previous 
published work suggested that the clear cell (CC) variant of ovarian 
carcinoma only had an 11% response rate as compared to serous 
tumours (72.5%). Survival was also poorer. We have evaluated the 
characteristics, PBC response rates and outcomes of our 
Endometrioid(E) and CC patients.
   Methods: Between 1984-2001, after central pathology review, data 
was prospectively collected for 267 patients with pure E, and 88 
patients withpure CC ovarian cancers.
    Results: Age, stage distribution, surgical debulking status, 
performance status and proportion receiving PBC were the same for 
both tumour subtypes. E tumours had significantly more concurrent 
uterine malignanciesthan CC (p=0.024). Of those who received 
chemotherapy 165/194 E patientsreceived PBC. 103/194 had 
radiological or Rustin Ca125 evaluable disease after surgery. PBC 
response rates were significantly higher for E tumours (63%) than for 
CC (36%,p=0.001). Overall survival and progression free survival was 
significantly better for E tumours with  stage III disease compared with 
CC (p= 0.001and 0.004 respectively). Debulking to <2cmsignificantly 
improved survival for both CC and E (p<0.0001).
    Conclusion: Response rates to PBC and survival for stage III are 
better inE tumours than CC. This analysis may have implications for 
future trial designs.  
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A SINGLE CENTRE AUDIT OF BLADDER CANCER. Jeetesh 
M Bhardwa*, Bharat K Sangtani, F I Chinewundoh, A M I Paris,  
C G Fowler, Vinod H Nargund 
Aim – To quantify the in patient work generated due to bladder 
cancer (TCC) and the need to develop new markers to monitor it. 
Method – Retrospective audit of in patient activity due to a 
diagnosis of TCC for the years 1998, 1999,2000 at the Urology
department at St. Bartholomews Hospital, London. 
Findings - There were 433 patients who had a total of 1188 
admissions/ episodes (An average of 2.7 episodes per patient). 
Patient demographics - Average age = 69.9 years (Median = 71 
years). Range = 31 years to 91 years. Male = 327 (75%) Females =
106 (25%) 
Procedures carried out in three years were as follows: 
TURBT = 548, Cystoscopy (under GA) = 168, Cystodiathermy
(under GA) = 168; Cystectomy = 14. 
That is an average of 295 endoscopic procedures per year. 
A total of 264 instillations of intravesical Chemotherapy in three 
years were performed. This was received by 52 patients in all with 
an average of 5.1 instillations per patient. 
Conclusion - A lot of resources are spent in treating and 
monitoring bladder cancer patients. If all the flexible cystoscopies
and Out Patients appointments are taken into consideration then the 
impact on the resources is even greater. This data justifies further 
research into markers of bladder cancer. In particular superficial 
bladder cancer that is at high risk of progressing to muscle invasive 
disease needs to be differentiated from that which is at low risk. 
These patients can then be followed up more efficiently and 
effectively.
P188 
EARLY (60-DAY) MORTALITY RATES, IN GI CANCER 
PATIENTS TREATED WITHIN RANDOMISED TRIALS, AT THE
ROYAL MARSDEN HOSPITAL.
Ourania Katopodis*, Paul J Ross, Andy R Norman, David Cunningham. 
Royal Marsden Hospital, Sutton, Surrey, SM2 5PT 
Aim: To document the 60 day all cause mortality rate, during
chemotherapy, for patients with oesophagogastric (O-G), pancreatic 
(panc.) and colorectal (CRC) cancer. 
Procedure: We conducted an analysis of 1720 patients with a minimum
follow up of 60 days treated within randomised trials. Kaplan Meier 
survival curves were used to calculate the all cause mortality and 95% 
confidence intervals (CI). Causes of death were classified as treatment 
related (toxicities), disease related or vascular syndrome (MI, CVA or
PE). Patients with O-G cancer were divided into those treated with 
platinum containing combinations and those unable to tolerate it. These 
patients received infused 5FU with or without mitomycin C. 
Results: (Table) 
Significance: This study provides a bench mark for assessing the safety
of regimens used in these disease settings. 
Conclusions: Site of primary determines 60 day mortality. The rate of
treatment related and vascular syndrome induced deaths is low (<1.8%). 
The majority of deaths within 60 days, in patients with advanced disease, 
were disease related. Only 1 patient (0.2%) died in the first 60 days
(cause of death: MI) of adjuvant chemotherapy for CRC. 
Group N  60 day
mortality CI 
Treatm.
related 
deaths 
Disease 
related 
deaths 
Vascular 
syndrome
deaths 
Advanced
CRC 609 3.4  % 2.3 - 
5.2  0.1 %  3.3 %  0 % 
Adjuvant
CRC 577 0.2  % 0.0 - 
1.2  0 %  0 %  0.2 % 
O-G
Platinum 254 6.3  % 3.9 - 
10.1  0.4 %  4.7 %  1.2 % 
O-G Non 
platinum 109 8.3  % 4.4 - 
15.3  0 %  7.4 %  0.9 % 
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